

Personal information

First name / Surname	HURLE Rodolfo
Address	8, Merula, 24129, Bergamo, Italy
Nationality	Italian
Date of birth	01/07/1962

Work experience

Dates	04/01/2011 - Today
Occupation or position held	Activity in the clinical field
Main activities and responsibilities	Medical Director
Name and address of employer	Istituto Clinico Humanitas (IRCCS) - - ROZZANO (MI)
Dates	01/01/2011 - Today
Occupation or position held	Subject Expert
Main activities and responsibilities	Subject Expert - Rete Oncologica Lombarda (ROL) Bladder Cancer
Name and address of employer	Regione Lombardia
Dates	02/01/1998 - 01/01/2011
Occupation or position held	Activity in the clinical field
Main activities and responsibilities	Medical Director
Name and address of employer	Humanitas Gavazzeni - - (BG)
Dates	01/01/1991 - 01/01/1998
Occupation or position held	Activity in the clinical field
Main activities and responsibilities	Medical Director
Name and address of employer	Ospedali Riuniti Bergamo - - Bergamo
Dates	01/01/1989 - 01/01/1990
Occupation or position held	Scholar Fellow
Main activities and responsibilities	College Scholarship
Name and address of employer	Fondazione Centro San raffaele del monte Tabor (IRCCS) - - MILANO

Education and training

Date
Title of qualification awarded
Principal subjects/occupational skills covered
Name and type of organisation providing education and training

Dec 2020
National Academic Qualification as as Full Professor 1st level Professor
Urology
Ministry of Education, Uneversity and Research

Date
Title of qualification awarded
Principal subjects/occupational skills covered
Name and type of organisation providing education and training

Sept, 2018
National Academic Qualification as Full Professor 2nd level Professor
Urology
Ministry of Education, Uneversity and Research

Date
Title of qualification awarded
Principal subjects/occupational skills covered
Name and type of organisation providing education and training

01/07/1993
Graduated School Degree
Urology
Università degli Studi di MILANO - 7, Festa del Perdono, Mialn, Italy

Date
Title of qualification awarded
Principal subjects/occupational skills covered
Name and type of organisation providing education and training

25/10/1988
Degree
Faculty of Medicine and Surgery
Università degli Studi di MILANO - 7, Festa del Perdono, Mialn, Italy

Personal skills and competences

Mother tongue(s) **Italian**

Other language(s) **English**

Self-assessment

English

Understanding		Speaking		Writing
Listening	Reading	Spoken interaction	Spoken production	
B1	B2	B1	B2	B2

List of Research Products

1. Ferro M, Del Giudice F, Carrieri G, Busetto GM, Cormio L, Hurle R et al. The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort Analysis. *Cancers*, 2021, Vol13, 5276. DOI: <https://doi.org/10.3390/cancers13215276>
2. Hurle R, Guazzoni G, Colombo PG, et al. Oncofid-P-B: a novel treatment for BCG unresponsive carcinoma in situ (CIS) of the bladder: Results of a prospective European Multicentre study at 15 months from treatment start. *Urologic Oncology: Seminars and Original Investigations*. Available online 12 October 2021. DOI: <https://doi.org/10.1016/j.urolonc.2021.07.007>
3. Fasulo V, Regis F, Paciotti M, Persico F, Maffei D, Uleri A, Saita A, Hurle R et al. MP11-01 High-resolution Micro-ultrasound for local staging of prostate cancer: a prospective single-center experience. *The Journal of Urology*, Vol. 206, No. 3S, Supplement, September, 2021. DOI: <https://doi.org/10.1097/JU.0000000000001984.01>
4. Lonati C, Baumeister P, Afferi L, Lucerne, Mari A, Minervini A, Krajewski W, Hendricksen K, Montorsi F, Briganti A, Antonelli A, Roupert M, Masson-Lecomte A, Shariat SF, D'Andrea D, Soria F, Hurle R, et al. MP16-18: Survival outcomes after radical cystectomy versus conservative management for T1 High Grade Non-Muscle Invasive micropapillary bladder cancer: a multicenter collaboration by the European Association of Urology - Young Academic Urologists. *The Journal of Urology*; Vol. 206, No. 3S, Supplement, Sept 2021. DOI: <https://doi.org/10.1097/JU.0000000000002001.18>
5. Corbetta M, Chiereghin C, De Simone I, Solda G, Zuradelli M, Michele Giunta, Maffei D, Lughezzani G, Buffi NM, Hurle R, et al. MP60-14: Post-biopsy cell-free DNA in blood as a tool for molecular tests in localized prostate cancer. *The Journal of Urology*; Vol. 206, No. 3S, Supplement, Sept 2021. DOI: <https://doi.org/10.1097/JU.0000000000002094.11>
6. Diana P, Uleri A, Lughezzani G, Frego N, Avolio PP, Paciotti M, Maffei D, Hurle R et al. MP59-11: Single institution prospective validation and comparison of the Simplified PAdua Renal (SPARE) nephrometry system for the prediction mic achievement in robotic partial nephrectomy. *The Journal of Urology*, Vol. 206, No. 3S, Supplement, Sept 2021. DOI: <https://doi.org/10.1097/JU.0000000000002094.11>
7. Diana P, Lughezzani G, Uleri A, Frego N, Contieri R, Paciotti M, Fasulo V, Colombo PG, Buffi NM, Saita A, Casale P, Hurle R, Lazzeri M. PD09-11 Potential role of micro-ultrasound in the differentiation between muscle-invasive and non-muscle invasive bladder cancer: a prospective analysis. *The Journal of Urology*; Vol. 206, No. 3S, Supplement, September 2021. DOI: <https://doi.org/10.1097/JU.0000000000001977.11>
8. Maffei D, Paciotti M, Avolio PP, Frego N, Fasulo V, Pietro D, Contieri R, Uleri A, Lazzeri M, Hurle R et al. MP30-09: Diagnostic accuracy of MPMRI-US fusion and micro-ultrasound guided prostate biopsies for clinically significant prostate cancer detection. *The Journal of Urology*; Vol. 206, No. 3S, Supplement, Sept 2021. DOI: <https://doi.org/10.1097/JU.0000000000002027.09>
9. Contieri R, Frego N, Paciotti M, Diana P, Avolio PP, Uleri A, Maffei D, Fasulo V, Lazzeri M, Saita A, Buffi NM, Lughezzani G, Casale P, Guazzoni G, Hurle R. PD63-05: Oncological long-term outcomes of patients under active surveillance for low-grade bladder tumors: an update from bladder cancer italian active surveillance (bias) project. *The Journal of Urology*; Vol. 206, No. 3S, Supplement, Sept 2021. DOI: <https://doi.org/10.1097/JU.0000000000002107.05>
10. Uleri A, Rozzano, Lughezzani G, Frego N, Contieri R, Avolio PP, Maffei D, Colombo PG, Balzarini L, D'Orazio F, Rozzano, Buffi NM, Saita A, Casale P, Massimo Lazzeri, Rodolfo Hurle. PD63-09: Head-to-head comparison between high-resolution microultrasound imaging and multiparametric MRI in detecting and local staging of bladder cancer: the bus-miss protocol. *The Journal of Urology*; Vol. 206, No. 3S, Supplement, Sept 2021. DOI: <https://doi.org/10.1097/JU.0000000000002107.09>

11. Colombo PG, Cieri M, Zucali P, De Carlo C, Elefante G, Hurle R et al. PD42-11: The switching phenotype and intratumor plasticity in bladder carcinoma: a mono-institutional analysis of 211 muscle-invasive carcinoma with considerations for therapy. *The Journal of Urology*; Vol. 206, No. 3S, Supplement, Sunday, Sept 2021. DOI: <https://doi.org/10.1097/JU.0000000000002056.11>
12. Paciotti M, Contieri R, Fasulo V, Casale P, Saita A, Buffi NM, Lughezzani G, Diana P, Frego N, Guazzoni G, Lazzeri M, Hurle R. Active surveillance for recurrent Non-Muscle Invasive Bladder Cancer (NMIBC): which lessons have we learned during COVID-19 pandemia? *Minerva Urology and Nephrology*; 02 Aug 2021. DOI: <https://doi.org/10.23736/S2724-6051.21.04613-9>
13. Lonati C, Baumeister P, Afferi A, Mari A, Minervini A, Krajewski W, Azizi S, Hendricksen K, Martini A, Necchi A, Montorsi A, Briganti A, Colombo R, Taffuri A, Antonelli A, Cerruto AM, Roupert M, Masson-Lecomte A, Laukhtina E, D'Andrea D, Shariat SF, Soria F, Marra G, Gontero P, Contieri R, Hurle R et al. Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration. *European Urology Focus*, available online 19 Aug 2021. DOI: <https://doi.org/10.1016/j.euf.2021.07.015>
14. Avolio P, Lughezzani G, Paciotti M, Maffei D, Uleri A, Frego N, Hurle R, et al. The use of 29 MHz transrectal micro-ultrasound to stratify the prostate cancer risk in patients with PI-RADS III lesions at multiparametric MRI: A single institutional analysis. *Urologic Oncology: Seminars and Original Investigations*; 26 June 2021. DOI: <https://doi.org/10.1016/j.urolonc.2021.05.030>
15. Ferro M, Lucarelli G, De cobelli O, Dolce P, Terracciano D, Musi G, Porreca A, Busetto GM, Del Giudice F, Soria F, Gontero P, Cantiello F, Damiano R, Crocerossa F, Abu Farham AR, Autorino R, Vartolomei MD, Marchioni M, Mari A, Minervini A, Longo N, Celentano G, Chiancone F, Perdonà S, Del Prete P, DiTonno P, Battaglia M, Zamboni S, Antonelli A, Greco F, Russo IG, Hurle Rodolfo et al. A risk-group classification model in patients with bladder cancer under neoadjuvant cisplatin-based combination chemotherapy. *Future Oncology*; Vol.17 No 30, 19 Jul 2021 DOI: <https://doi.org/10.2217/fon-2020-1298>
16. Hurle R, Contieri R, Lazzeri M. Editorial Comment on "Surveillance Intensity in Intermediate Risk, Nonmuscle Invasive Bladder Cancer: Revisiting the Optimal Timing and Frequency of Cystoscopy." *Journal of urology*, Volume 206 Issue 1, July 2021, Page: 27-27. DOI: <https://doi.org/10.1097/JU.0000000000001689.01>
17. Contieri R, Paciotti M, Lughezzani G, Buffi NM, Frego N, Diana P, Fasulo V, Saita A, Casale P, Lazzari M, Guazzoni G, Hurle R. Long-term Follow-up and Factors Associated with Active Surveillance Failure for Patients with Non-muscle-invasive Bladder Cancer: The Bladder Cancer Italian Active Surveillance (BIAS) Experience. *European Urology Oncology*; Available online 28May 2021 In press, Corrected Proof. DOI: <https://doi.org/10.1016/j.euo.2021.05.002>
18. Ferro M, De Cobelli O, Musi G, Lucarelli G, Terracciano D, Pacella D, Muto T, Porreca A, Busetto GM, Del Giudice F, Soria F, Gontero P, Cantiello F, Damiano R, Crocerossa F, Abu Farhan AR, Autorino R, Vartolomei MD, Muto M, Marchioni M, Mari A, Scafuri L, Minervini A, Longo N, Chiancone F, Perdonà S, De Placido P, Verde A, Catellani M, Luzzago S, Mistretta FA, Ditunno A, Caputo VF, Battaglia M, Zamboni S, Antonelli A, Greco F, Russo GI, Hurle R, Crisan N, Manfredi M, Porpiglia F, Di Lorenzo G, Crocetto F, Buonerba C. Three vs. Four Cycles of Neoadjuvant Chemotherapy for Localized Muscle Invasive Bladder Cancer Undergoing Radical Cystectomy: A Retrospective Multi-Institutional Analysis. *Frontiers in oncology*; Vol 11, may 2021. DOI: <https://dx.doi.org/10.3389/fonc.2021.651745>
19. Frego N, Saita A, Casale P, Diana P, Contieri R, Avoglio PP, Lazzzeri M, Hurle R, et al. Feasibility, safety, and efficacy of ultrasound-guided transperineal laser ablation for the treatment of benign prostatic hyperplasia: a single institutional experience. *World Journal of Urology*, Apr 2021. DOI: <https://doi.org/10.1007/s00345-021-03685-7>
20. Petrelli F, Giannatempo P, Maccagnano C, Contieri R, Hurle R. Active surveillance for non-muscle invasive bladder cancer: A systematic review and pooled-analysis. *Cancer Treatment and research communication*; Vol 27, April 2021. DOI: <https://doi.org/10.1016/j.ctarc.2021.100369>
21. Ferro M, Babăţ DF, De Cobelli O, Musi G, Lucarelli G, Terracciano D, Ottavio De Cobelli, Gennaro

Musi, Giuseppe Lucarelli, Daniela Terracciano, Porreca A, Busetto GM, Del Giudice F, Soria F, Gontero P, Cantiello F, Damiano R, Papalia R, Scarpa RM, Abu Farhan AR, Autorino R, Brescia A, Marchioni M, Mari A, Minervini A, Longo N, Chiancone F, Perdonà A, Barone B, De Placido P, Catellani M, Bottero D, Ditunno P, Battaglia M, Zamboni S, Antonelli A, Greco F, Russo GI, Smelzo S, Hurle R, Crisan N, Manfredi M, Porpiglia F, Crocetto F, Buonerba C, Danilescu A, Vartolomei MD. Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy, *Future Science OA*; published online April 2021. DOI: <https://doi.org/10.2144/fsoa-2021-0008>

22. Paciotti M, Casale P, Colombo P, Fasulo V., Saita A, Lughezzani G, Contieri R, Buffi NM, Lazzeri M, Guazzoni G, Hurle R. Long-term Follow-up After En Bloc Transurethral Resection of Non-muscle-invasive Bladder Cancer: Results from a Single-center Experience. *European Urology Open Science*; Vol 26, April 2021, Pages 64-71. DOI: <https://doi.org/10.1016/j.euros.2021.01.015>
23. Hurle R, Contieri R, Casale P, et al. Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure. *Urologic Oncology: Seminars and Original Investigations*, Volume 39, Issue 3, March 2021, Pages 195.e7-195.e13. DOI: <https://doi.org/10.1016/j.urolonc.2020.09.017>
24. Ferro M, Marchioni M, Lucarelli G, Bartolomei MD, Soria F, Terracciano D, Mistretta FA, Luzzago S, Buonerba C, Cantiello F, Mari A, Minervini A, Vecchia A, Antonelli A, Musi G, Hurle R, et al. Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicentre study. *Minerva Urologica e Nefrologica*; 2021. DOI: <http://hdl.handle.net/11369/395342>
25. Ferro M, Di Mauro M, Cimino S, Morgia G, Lucarelli G, Abu Farhan AR, Vartolomei MD, Porreca A, Cantiello F, Damiano R, Busetto GM, Del Giudice F, Hurle R, et al. Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer. *Translational Andrology and Urology*; Feb 2021, 10(2): 626-635. DOI: <http://dx.doi.org/10.21037/tau-20-1272>

26. Corbetta M, Chiereghin C, De Simone I., Soldà GM., Zuradelli M., Giunta M., Lughezzani G., Nicolò Maria Bu NM., Hurle R., Saita A., Casale P., Asselta R., Lazzeri M., Guazzoni G., Duga S. Post-biopsy cell-free DNA from blood: an open window on primary prostate cancer genetics and biology. Research Square; 2021. DOI:<https://doi.org/10.3389/fonc.2021.654140>
27. Lazzeri M, Duga S, Azzolini E, Fasulo V, Buffi N, Saita A, Lughezzani G, Paraboschi EM, Hurle R, Nobili A, Cecconi M, Guazzoni G, Casale P, Asselta R. Impact of chronic exposure to 5-alpha reductase inhibitors on the risk of hospitalization for COVID-19: a case-control study in male population from two COVID-19 regional centers of Lombardy (Italy). *Minerva Urologica e Nefrologica* = The Italian Journal of Urology and Nephrology; 13 Jan 2021. DOI:<https://doi.org/10.23736/s0393-2249.20.04081-3>
28. Oresta B., Pozzi C., Braga D., Hurle R., Lazzeri M., Colombo P., Frego N., Erreni M., Faccani C., Elefante G., Barcella M., Guazzoni G., Rescigno M. Metabolic reprogramming controls the induction of immunogenic cell death and efficacy of chemotherapy in bladder cancer. *Science Translational Medicine*; 2021. Vol. 13, Issue 575, eaba6110. DOI:<https://doi.org/10.1126/scitranslmed.aba6110>
29. Oresta B, Braga D, Lazzeri M, Frego N, Saita A, Faccani C, Fasulo V, Colombo P, Guazzoni G, Hurle R, Rescigno M. The Microbiome of Catheter Collected Urine in Males with Bladder Cancer According to Disease Stage. *Journal of Urology*, Vol 205 Issue, Jan 2021. Pages 86-93. DOI:<https://www.auajournals.org/doi/abs/10.1097/JU.0000000000001336#:~:text=https%3A%2Fdoi.org%2F10.1097%2FJU.0000000000001336>
30. Contieri R, Maccagnano C, Hurle R. Overview of the Italian Experience in Surgical Management of Bladder Cancer During First Month of COVID-19 Pandemic - Beyond the Abstract. *UroToday*, Jan 2021. <https://www.urotoday.com/recent-abstracts/covid-19-and-genitourinary-cancers/127095-overview-of-the-italian-experience-in-surgical-management-of-bladder-cancer-during-first-month-of-covid-19-pandemic-beyond-the-abstract.html>
31. Oresta B, Pozzi C, Braga D, Hurle R, et al. Mitochondrial metabolic reprogramming controls the induction of immunogenic cell death and efficacy of chemotherapy in bladder cancer. *Science Translation Medicine*, Jan 2021, Vol 13 Issue 575. DOI:<https://stm.sciencemag.org/content/13/575/eaba6110.abstract#:~:text=DOI%3A%2010.1126%2Fsci%2Ftranslmed.aba6110>
32. Maccagnano VC, Rocchini R, Montanari E, Conti GN, Petralia G, Dehò F, Bryan KA, Contieri R, Hurle R. Overview of the Italian experience in surgical management of bladder cancer during first month of COVID-19 pandemic. *Archivio Italiano di Urologia Andrologia*, Dec 2020. DOI:<https://air.unimi.it/handle/2434/801418#:~:text=http%3A%2Fdx.doi.org%2F10.4081%2Faiua.2020.4.275>
33. Diana P, Lughezzani G, Uleri A, Casale P, Saita A, Hurle R, et al. Multi-institutional Retrospective Validation and Comparison of the Simplified PADUA RENal Nephrometry System for the Prediction of Surgical Success of Robot-assisted Partial Nephrectomy. *European Urology Focus*, Nov 2020. DOI:<https://doi.org/10.1016/j.euf.2020.11.003>
34. Maffei D, Paciotti M, Domanico L, Regis F, Fasulo V, Avolio P, Colombo P, Hurle R, et al. Diagnostic performance of micro-ultrasound in patients under active surveillance for low-risk prostate cancer. *European Urology Open Science* 21: S125, Nov 2020. DOI:[https://doi.org/10.1016/S2666-1683\(20\)36188-7](https://doi.org/10.1016/S2666-1683(20)36188-7)
35. Lughezzani G, Maffei D, Saita A, Paciotti M, Diana P, Buffi NM, Colombo P, Elefante GM, Hurle R. Diagnostic Accuracy of Microultrasound in Patients with a Suspicion of Prostate Cancer at Magnetic Resonance Imaging: A Single-institutional Prospective Study. Available online 15 October 2020 In Press, Corrected Proof. DOI:<https://doi.org/10.1016/j.euf.2020.09.013>
36. Busetto GM, Porreca A, Del Giudice F, Maggi M, D'Agostino D, Romagnoli D, Musi G, Lucarelli G, Palmer K, Colonna di Paliano A, Muto M, Hurle R, et al. SARS-CoV-2 Infection and High-Risk Non-Muscle-Invasive Bladder Cancer: Are There Any Common Features? *Urologia Internationalis*, Aug 2020, vol 104 No7-8. DOI:<https://doi.org/10.1159/000509065>

37. Hurle R, Casale P, Morengi E, et al. Intravesical gemcitabine as bladder-preserving treatment for BCG unresponsive non-muscle-invasive bladder cancer. Results from a single-arm, open-label study. *BJU International Compass*, Jul 2020. DOI: <https://bjui-journals.onlinelibrary.wiley.com/doi/full/10.1002/bco2.28#:~:text=https%3A//doi.org/10.1002/bco2.28>
38. Saita A, Lughezzani G, Buffi NM, Hurle R, et al. Assessing the Feasibility and Accuracy of High-resolution Microultrasound Imaging for Bladder Cancer Detection and Staging. *European Urology* Volume 77, Issue 6, June 2020, Pages 727-732. DOI: <https://doi.org/10.1016/j.eururo.2019.03.044>
39. Ferro M, Katalin MO, Buonerba C, Raluca M, Cantiello F, Musi G, Di Stasi S, Hurle R, et al. Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. *Urologic Oncology: Seminars and Original Investigations*, Volume 38, Issue 5, May 2020. Pages 459-464. DOI: <https://www.sciencedirect.com/science/article/abs/pii/S1078143920300570#:~:text=https%3A//doi.org/10.1016/j.urolonc.2020.02.016>
40. Lazzeri M, Azzolini E, Buffi NM, Fasulo V, Persico F, Saita A, Hurle R, et al., Impact of anti-androgenic therapies on COVID-19: an observational study in male population from a COVID-19 regional centre of Lombardy (Italy). *MedRxiv*, Apr 2020. DOI: <https://doi.org/10.1101/2020.04.20.20068056>
41. Lopci E, Lughezzani G, Castello A, Saita A, Colombo P, Hurle R, et al. Prospective Evaluation of 68Ga-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography in Primary Prostate Cancer Diagnosis. *European Urology Focus*, Available online 17 April 2020 In Press, Corrected Proof. DOI: <https://doi.org/10.1016/j.euf.2020.03.004>
42. Soria F, D'Andrea D, Moschini M, Giordano A, Mazzoli S, Pizzuto G, Hurle R, et al. Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients? *Urologic Oncology: Seminars and Original Investigations*, Volume 38, Issue 3, March 2020, Pages 77.e1-77.e7. DOI: <https://www.sciencedirect.com/science/article/abs/pii/S107814391930328X#:~:text=https%3A//doi.org/10.1016/j.urolonc.2019.08.010>
43. Hurle R, Maccagnano C. Active surveillance for recurrent low-grade non-muscle-invasive bladder cancer: Can we take any advantage from the COVID-19 crisis? *Arab Journal of urology*, 2020, VOL. 18, NO. 2, 65–66. DOI: <https://doi.org/10.1080/2090598X.2020.1772031>
44. Lista G, Lughezzani G, Buffi NM, Saita A, Vanni E, Hurle R, et al. Early Catheter Removal After Robot-assisted Radical Prostatectomy: Results from a Prospective Single-institutional Randomized Trial (Ripreca Study). *European Urology Focus*, Volume 6, Issue 2, 15 March 2020, Pages 259-266. DOI: <https://doi.org/10.1016/j.euf.2018.10.013>
45. Oresta B, Hurle R, et al. Characterization of the urinary microbiota in bladder cancer patients. *Journal of Clinical Oncology*, Abstract 535, Feb 2020, Vol 38 Issue 15 Suppl. DOI: https://doi.org/10.1200/jco.2020.38.6_suppl.535
46. Hurle R, Guazzoni G, Colombo P, et al. PD12-01 “ONCOFID-P-B for the treatment of bcg unresponsive carcinoma in situ (cis) of bladder: preliminary results of european multicentre phase 1 study at the end of 12 consecutive weeks intensive course and during ongoing monthly maintenance phase.” *Journal of urology*, Vol 213 4S, Supplement, May 2020. DOI: <https://doi.org/10.1097/JU.0000000000000846.01>
47. Persico F, Lazzeri M, Lughezzani G, Gatto P, Hurle R. CASE 2: The effect of bacillus calmette-guérin(bcg) instillations on the immune system: a case report of hypersensitivity pneumonitis during the covid-19 pandemic. *Case Collection Oncology and Complication*, Aug 2020 (*Archivio Italiano di Urologia e Andrologia* 2021, Vol 93 Pages 71-76. DOI: <https://doi.org/10.4081/aiua.2021.1.71>
48. Frego N, Diana P, Regis F, Maffei D, Domanico L, Paciotti M, Fasulo V, Bevilacqua G, Lughezzani G, Saita A, Casale P, Buffi NM, Guazzoni G, Lazzeri M, Hurle R. PD12-04 “Oncological long-term safety and pathological outcome evaluation for patients under active surveillance for recurrent low-risk non-muscle invasive bladder cancer: result from bladder cancer italian active surveillance

(BIAS) project." Journal of urology, Vol 213 4S, Supplement, May 2020.

DOI:<https://www.auajournals.org/doi/abs/10.1097/JU.0000000000000846.04#:~:text=https%3A/doi.org/10.1097/JU.0000000000000846.04>

49. Maffei D, Staerman F, Paciotti M, Colombo P, Elefante MG, Domanico L, Regis F, Bevilacqua G, Fasulo V, Lazzeri M, Rodolfo Hurle R, et al. MP23-05 "The utility of micro-ultrasound in patients under active surveillance for low-risk prostate cancer: a PRIAS study extension". Journal of urology, Vol 213 4S, Supplement, May 2020. DOI:<https://doi.org/10.1097/JU.0000000000000856.05>
50. Diana P, Lughezzani G, Frego N, D'Orazio F, Colombo P, Maffei D, Paciotti M, Fasulo V, Regis F, Domanico L, Bevilacqua G, Casale P, Buffi NM, Hurle R, et al. PD12-06 "Head-to-head comparison between micro-ultrasound and MRI in the differentiation between muscle-invasive and non-muscle invasive bladder cancer: results from the bladder microus versus mri cancer imaging staging study (bus-miss) protocol". Journal of urology, Vol 213 4S, Supplement, May 2020. DOI:<https://doi.org/10.1097/JU.0000000000000846.06>
51. Colombo P, Elefante GM, Lazzeri M, De Carlo C, D'antonio F, Giordano L, Zucali P, Guazzoni G, Hurle R, et al. MP55-07 "Predictive and prognostic role of a simple immuno-phenotypical score in clinical management of patients with pT2 invasive urothelial carcinoma". Journal of urology, Vol 213 4S, Supplement, May 2020. DOI:<https://doi.org/10.1097/JU.0000000000000924.07>
52. Paciotti M, Fasulo V, Lazzeri M, Domanico L, Regis F, Frego N, Davide Maffei D, Pietro Diana P, Giulio Bevilacqua G, Alessio Benetti A, Roberto Peschechera R, Lughezzani G, Saita A, Buffi N, Casale P, Guazzoni G, Hurle R. PD12-11 "Long-term follow-up in high risk non muscle invasive bladder cancer "en-bloc" resection." Journal of urology, Vol 213 4S, Supplement, May 2020. DOI:<https://doi.org/10.1097/JU.0000000000000846.011>
53. Frego N, Domanico L, Maffei Di, Paciotti M, Diana P, Regis F, Bevilacqua G, Fasulo V, Peschechera R, Lazzeri M, Hurle R, et al. MP15-16 "Laser lithotripter settings according to endoscopic view: how can we optimise the outcome? A simple way to optimise the treatment strategy". Journal of urology, Vol 213 4S, Supplement, May 2020. DOI:<https://doi.org/10.1097/JU.0000000000000840.016>
54. Oresta B, Chiara Pozzi C, Daniele Braga D, Rodolfo Hurle R, et al. MP01-07 "Mitomycin C sensitive tumor cells generate an inflammatory secretome capable of inducing anti-tumor immune responses." Journal of urology, Vol 213 4S, Supplement, May 2020. DOI:<https://doi.org/10.1097/JU.0000000000000815.07>
55. Colombo P, Andrea Zucali PA, De Carlo C, Giordano L, Hurle R, et al. Retrospective analysis of an alternative immuno-score in clinical management of patients with pT2 urothelial carcinoma. Journal of Clinical Oncology, Abstract e17038, Feb 2020. DOI:https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e17038#:~:text=ARTICLE%20CITATION-DOI%3A%2010.1200/JCO.2020.38.15_suppl.e17038,-Journal%20of%20Clinical%20Oncology%2038
56. Zucali PA, Colombo P, De Carlo C, Giordano L, Hurle R, et al. The neural phenotype in invasive urothelial carcinoma patients: Alternative score detection and prognostic implication. Journal of Clinical Oncology, Abstract e17037, Feb 2020, Vol 38 Issue 15 Suppl. DOI:https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e17037#:~:text=DOI%3A-10.1200/JCO.2020.38.15_suppl.e17037,-Journal%20of%20Clinical%20Oncology%2038
57. Hurle R, Guazzoni G, Colombo P, et al. Oncofid-P-B for the treatment of BCG unresponsive carcinoma in situ (CIS) of bladder: Results of European multicenter phase I study at the end of 12- consecutive weeks intensive course. Journal of Clinical Oncology, Abstract 486, Feb 2020, Vol 38 Issue 15 Suppl. DOI:https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.6_suppl.486#:~:text=DOI%3A-10.1200/JCO.2020.38.6_suppl.486,-Journal%20of%20Clinical%20Oncology%2038
58. Fasulo V, Lazzeri M, Corbetta M, Paciott Mi, Maffei D, Soldà G, Domanico L, Frego N, Federica Regis F, Diana P, Asselta R, Buffi N, Casale P, Saita A, Chiereghin C, Lughezzani G, Zuradelli M, Hurle R, et al. TMRSS2: ERG expression in prostate cancer—Imaging and clinicopathological correlations. Journal of Clinical Oncology, Abstract 284, Feb 2020, Vol 38 Issue 15 Suppl.

DOI:https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.6_suppl.284#:~:text=DOI%3A-10.1200/JCO.2020.38.6_suppl.284,-Journal%20of%20Clinical%20Oncology%2038

59. Maffei D, Paciotti M, Lazzeri M, Frego N, Fasulo V, Diana P, Regis F, Elefante GM, Colombo P, Saita A, Hurle R, et al. Micro-ultrasound versus multiparametric MRI in the detection of prostate cancer: Results from a prospective single center trial. *European Urology Supplements* Vol18, Issue 11, November 2019, Page e3410. DOI:[https://doi.org/10.1016/S1569-9056\(19\)34585-3](https://doi.org/10.1016/S1569-9056(19)34585-3)
60. Diana P, Lughezzani G, Lazzeri M, Frego N, Maffei D, Paciotti M, Fasulo V, Domanico L, Regis F, Bevilacqua G, Saita A, Buffi NM, Casale P, D'orazio F, Balzarini L, Guazzoni G, Hurle R, et al. P122 - Preliminary Results for The Bladder microUS vs. MRI cancer imaging Staging Study: The BUS-MISS. *European Urology Supplements*, Vol 18, Issue 11, Nov 2019, Page e3565. DOI:[https://doi.org/10.1016/S1569-9056\(19\)34700-1](https://doi.org/10.1016/S1569-9056(19)34700-1)
61. Hurle R, Casale P, Saita R, et al. Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA-based urine test, in active surveillance (AS) patients with recurrent non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Italian Active Surveillance (BIAS) project. *World Journal of Urology* volume 38, pages 2215–2220 (2020), Nov 2019. DOI:<https://doi.org/10.1007/s00345-019-03002-3>
62. Paciotti M, Maffei D, Lazzeri M, Fasulo V, Bevilacqua G, Diana P, Frego N, Elefante GM, Colombo P, Casale P, Hurle R, et al. P005 - Micro-ultrasound target biopsies for the diagnosis of clinically significant prostate cancer: Results from a large single-center experience. *European Urology Supplements*, Vol 18, Issue 11, Nov 2019, Page e3418. DOI:[https://doi.org/10.1016/S1569-9056\(19\)34591-9](https://doi.org/10.1016/S1569-9056(19)34591-9)
63. Paciotti M, Maffei D, Lazzeri M, Frego N, Diana P, Regis F, Domanico L, Colombo P, Casale P, Saita AR, Hurle R, et al. Real-time micro-ultrasound guiding of systematic prostate biopsies: Preliminary results from a single-institutional experience. *European Urology Supplements*, Vol 18, Issue 11, Nov 2019, Pages e3421-e3422. DOI:[https://doi.org/10.1016/S1569-9056\(19\)34594-4](https://doi.org/10.1016/S1569-9056(19)34594-4)
64. Maffei D, Paciotti M, Lazzeri M, Zhang L, Frego N, Colombo P, Casale P, Hurle R, et al. SC313 - Assessing the diagnostic accuracy of micro-ultrasound for the detection of clinically significant prostate cancer in the initial biopsy setting. *European Urology Supplements* Vol 18, Issue 9, October 2019, Pages e3341-e3342. DOI:[https://doi.org/10.1016/S1569-9056\(19\)33793-5](https://doi.org/10.1016/S1569-9056(19)33793-5)
65. Lazzeri M, Casale P, Saita A, Lughezzani G, Buffi N, Frego N, Fasulo V, Paciotti M, Bevilacqua G, Domanico L, Maffei D, Diana P, Hurle R, et al. Clinical performance of Xpert Bladder Cancer (BC) Monitor, a mRNA-based urine test, in active surveillance (AS) patients with recurrent non-muscle-invasive bladder cancer (NMIBC): results from the Bladder Cancer Italian Active Surveillance (BIAS) project. *European Urology Supplements*, Vol 18, Issue 9, Oct 2019, Page e3249. DOI:[https://doi.org/10.1016/S1569-9056\(19\)33636-X](https://doi.org/10.1016/S1569-9056(19)33636-X)
66. Regis F, Frego N, Diana P, Lughezzani G, Bevilacqua G, Domanico L, Paciotti M, Fasulo V, Maffei D, Peschechera R, Lazzeri M, Hurle R, et al. Cost-effectiveness of reusable ureterorenoscopes in a high volume single center. *European Urology Supplements*, Vol 18, Issue 7, Oct 2019, Page e2942. DOI:[https://doi.org/10.1016/S1569-9056\(19\)33103-3](https://doi.org/10.1016/S1569-9056(19)33103-3)
67. Paciotti M, Maffei D, Lazzeri M, Domanico L, Fasulo V, Elefante G, Hurle R, et al. SC240 - Micro-ultrasound target biopsies for the diagnosis of clinically significant prostate cancer: Results from a large single-centre experience. *European Urology Supplements*, Vol 18, Issue 9, Oct 2019, Pages e3299-e3300. DOI:[https://doi.org/10.1016/S1569-9056\(19\)33720-0](https://doi.org/10.1016/S1569-9056(19)33720-0)
68. Paciotti M, Maffei D, Lazzeri M, Frego N, Diana P, Elefante G, Saita A, Casale P, R. Hurle R, et al. SC241 - Can real-time high-resolution micro-ultrasound guided biopsies reduce the number of patients undergoing systematic prostate biopsies? preliminary results from a single-institutional experience. *European Urology Supplements*, Vol 18, Issue 9, Oct 2019, Page e3300. DOI:[https://doi.org/10.1016/S1569-9056\(19\)33721-2](https://doi.org/10.1016/S1569-9056(19)33721-2)
69. Diana P, Regis F, Frego N, Piccoli F, Domanico L, Lughezzani G, Bevilacqua G, Paciotti M, Fasulo V, Maffei D, Hurle R, et al. UP042 - Case report of a 75-year-old male with matrix stone disease: An

alternative treatment. *European Urology Supplements*, Vol 18, Issue 7, Oct 2019, Page e2999.
DOI:[https://doi.org/10.1016/S1569-9056\(19\)33151-3](https://doi.org/10.1016/S1569-9056(19)33151-3)

70. Diana P, Lughezzani G, Bevilacqua G, Domanico L, Paciotti M, Fasulo V, Frego N, Maffei D, Regis F, Casale P, Saita A, Hurle R, et al. VJY04 Robot-Assisted ureteroplasty and ureteral reimplantation for nonrefluxing primary obstructing megaureter. *European Urology Supplements* 18(6): e2728, Sept 2019. DOI:[http://dx.doi.org/10.1016/S1569-9056\(19\)32825-8](http://dx.doi.org/10.1016/S1569-9056(19)32825-8)
71. Zuradelli M, Buffi N, Bianchi P, Ripamonti CB, Barile M, Casale P, Saita A, Lughezzani G, Hurle R, et al. Screening of BRCA2 mutated men for detection of prostate cancer: Preliminary results from a national high volume cancer center. *Journal of Clinical Oncology*, Abstract e16567, May 2019, Vol 37, no. 15_suppl. https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.e16567
72. Lughezzani G, Saita A, Lazzeri M, Paciotti M, Maffei D, Lista G, Hurle R. et al. Comparison of the Diagnostic Accuracy of Micro-ultrasound and Magnetic Resonance Imaging/Ultrasound Fusion Targeted Biopsies for the Diagnosis of Clinically Significant Prostate Cancer *European Urology Oncology*, Volume 2, Issue 3, May 2019, Pages 329-332.
DOI:<https://doi.org/10.1016/j.euo.2018.10.001>
73. Hurle R, Lazzeri M, Saita A, et al. Predictive factors for progression of patients with carcinoma in situ of the bladder at long-term follow-up: pure versus non-pure CIS. *Minerva Urologica e Nefrologica = The Italian Journal of Urology and Nephrology*, 28 May 2019, 71(4):406-412.
DOI:<https://doi.org/10.23736/s0393-2249.19.03254-5>
74. Hurle R, Casale P, Lazzari M, et al. En bloc re-resection of high-risk NMIBC after en bloc resection: results of a multicenter observational study, 38, pages703–708 (2020), May 2019.
DOI:<https://doi.org/10.1007/s00345-019-02805-8>
75. Hurle R, Lazzari M, Guazzoni G, et al. PD18-04 “A phase 1 safety study of ONCOFID-P-B administered for 12 consecutive weeks in BCG unresponsive/intolerant patients with bladder carcinoma in situ (CIS): preliminary results”. *Journal of urology*, Vol 201 4S, Supplement, Apr 2019.
DOI:<https://doi.org/10.1097/01.JU.0000555576.38955.91>
76. Buffi NM, Saita A, Guazzoni G, Lughezzani G, Casale P, Hurle R, et al. LBA-08 “Screening of BRCA2 mutated men for detection of prostate cancer: preliminary results from a national high volume cancer centre. *Journal of urology*, Vol 201 4S, Supplement, Apr 2019.
DOI:<https://doi.org/10.1097/01.JU.0000557500.15711.50>
77. Hurle R, Casale P, Saita A, et al. PD13-11 “Up-date of pathological outcome and subjective definition of failure for patients under active surveillance for recurrent low-risk non-muscle invasive bladder cancer: result from bladder cancer italian active surveillance (BIAS) project”. *Journal of urology*, Vol 201 4S, Supplement, Apr 2019.
DOI:<https://doi.org/10.1097/01.JU.0000555391.13737.df>
78. Hrle R, Saita A, Lazzeri M, et al. PD18-05 “Xpertbladder monitor test for failure definition of patients under active surveillance for recurrent low-risk non-muscle invasive bladder cancer (NMIBC) with negative cytology”. *Journal of urology*, Vol 201 4S, Supplement, Apr 2019.
DOI:<https://doi.org/10.1097/01.JU.0000555577.46578.24>
79. Lopci E, Saita A, Lughezzani G, Castello A, Colombo P, Buffi NM, Hurle R. et al. MP36-20 “Potentials of 68ga-prostate specific membrane antigen PET/CT for primary diagnosis of prostate cancer.” *Journal of urology*, Vol 201 4S, Supplement, Apr 2019.
DOI:<https://doi.org/10.1097/01.JU.0000556030.18441.0a>
80. Maffei D, Paciotti M, Lazzeri M, Colombo P, Fasulo V, Domanico L, Casale P, Saita A, Hurle R, et al. MP36-09 “diagnostic accuracy of targeted prostate biopsies: results from a prospective trial comparing micro-ultrasound with multiparametric MRI for the detection of prostate cancer”. *Journal of urology*, Vol 201 4S, Supplement, Apr 2019.
DOI:<https://doi.org/10.1097/01.JU.0000556019.01408.62>
81. Casale P, Buffi NM, Lumezzani G, Maffei D, Dell’Olio P, Paciotti M, Fasulo V, Domanico L, Bevilacqua G, Saita A, Lazzari M, Hurle r, et al, V10-01 “Robot-assisted partial nephrectomy: techniques and outcomes from the transatlantic robotic nephron-sparing surgery (TRONES) study

- group." *Journal of urology*, Vol 201 4S, Supplement, Apr 2019.
DOI:<https://doi.org/10.1097/01.JU.0000557181.42968.09>
82. Oresta B, Pozzi C, Hurle R, et al. MP63-17 Mitomycin c triggers immunogenic cell death in bladder cancer cells. *Journal of Urology*, Vol 201, Issue Supplement 4, April 2019, Page: e903-e903.
DOI:<https://doi.org/10.1097/01.JU.0000556860.69563.b2>
 83. Saita A, Villa L, Paciotti M, Fasulo V, Casale P, Lughezzani G, Buffi NM, Hurle R, et al. MP23-17 In vitro and in vivo new evidence for flexor vue deflecting endoscopic system use: optimization of the stone free rate (SFR) after RIRS. *The Journal of Urology*, Vol 201, Issue Supplement 4, Apr 2019, Page: e332-e332 DOI:<https://doi.org/10.1097/01.JU.0000555622.35797.1c>
 84. Buffi N, Saita A, Zuradelli M., Casale P, Hurle R, et al. Clinical impact of male BRCA2 germline pathogenic mutation: Preliminary results from a National Clinical Research Hospital. *European Urology Supplements* 18(1): e1807, Mar 2019. DOI:[https://doi.org/10.1016/S1569-9056\(19\)31307-7](https://doi.org/10.1016/S1569-9056(19)31307-7)
 85. Saita A, Hurle R, Casale P, et al. Up-date of pathological outcome and subjective definition of failure for patients under active surveillance for recurrent low-risk non-muscle invasive bladder cancer: Result from Bladder Cancer Italian Active Surveillance (BIAS) project. *European Urology Supplements* 18(1): e938, Mar 2019. DOI:[https://doi.org/10.1016/S1569-9056\(19\)30682-7](https://doi.org/10.1016/S1569-9056(19)30682-7)
 86. Soria F, D'Andrea D, Moschini M, Kantonsspital L, Hurle R, et al. Predictive factors for the absence of residual disease at repeated TURBT: Can we avoid a repeat TURBT in selected patients? *European Urology Supplements* 18(1): e778, Mar 2019. DOI:[https://doi.org/10.1016/S1569-9056\(19\)30569-X](https://doi.org/10.1016/S1569-9056(19)30569-X)
 87. A.R. Saita Ar, Hurle R, Buffi N, et al. High resolution micro-ultrasound imaging for bladder cancer: A gender and stage-oriented assessment. *European Urology Supplements* 18(1): e2230, Mar 2019. DOI:[http://dx.doi.org/10.1016/S1569-9056\(19\)31614-8](http://dx.doi.org/10.1016/S1569-9056(19)31614-8)
 88. Casale P, Saita A, Lazzeri M, Lughezzani G, Hurle R, et al. p2PSA for predicting biochemical recurrence of prostate cancer earlier than total prostate-specific antigen after radical prostatectomy: an observational prospective cohort study. *Minerva Urologica e Nefrologica = The Italian Journal of Urology and Nephrology*, 28 Jan 2019, 71(3):273-279. DOI:<https://doi.org/10.23736/s0393-2249.19.03279-x>
 89. Badenchini F, Zollo F, Altieri V, Barbaresi U, Battaglia M, Enrico B, Borghesi M, Cicchetti G, Colombo P, Colecchia M, Da Pozzo L, Ditunno P, Fabiano M, Fiorentino M, Frizzi J, Frego E, Gallucci M, Grimaldi G, Guazzoni G, Hurle R, et al. SiUro PRIAS ita working group: 9-year experience of active surveillance. *Anticancer Research*, 2019, Vol 39 Issue 3, Pages 1596-1598.
<http://hdl.handle.net/11699/7710>
 90. Vartolomei MD, FerroM, Cantiello F, Lucarelli G, Di Stasi S, Hurle R, et al. Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non-muscle-invasive Bladder Cancer. *Clinical Genitourinary Cancer* Volume 16, Issue 6, December 2018, Pages 445-452. DOI:<https://doi.org/10.1016/j.clgc.2018.07.003>
 91. Cantiello F, Russo G, Vartolomei MD, AbuFarhana AR, Terracciano D, Musi G, Lucarelli G, Di Stasi SM, Hurle R. et al. Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non-muscle-invasive Urothelial Bladder Cancer. *European Urology Oncology*, Volume 1, Issue 5, Oct 2018, Pages 403-410. DOI:<https://doi.org/10.1016/j.euo.2018.06.006>
 92. Ferro M, Di Lorenzo G, Buonerba C, Lucarelli G, Russo GI, Cantiello F, Abu Farhan AR, Di Stasi S, Musi G, Hurle R, et al. Predictors of Residual T1 High Grade on Re-Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder Cancer, *Journal of Cancer* Oct 2018, Vol. 9. DOI:<https://dx.doi.org/10.7150%2Fjca.26129>
 93. Hurle R, Colombo P, Lazzeri M, et al. Pathological Outcomes for Patients Who Failed To Remain Under Active Surveillance for Low-risk Non-muscle-invasive Bladder Cancer: Update and Results from the Bladder Cancer Italian Active Surveillance Project. *European Urology Oncology*, Volume 1, Issue 5, Oct 2018, Pages 437-442. DOI:<https://doi.org/10.1016/j.euo.2018.05.006>

94. Hurle R, Maccagnano C. Enhancing the Quality of Transurethral Resection: The Importance of a Complete TURB and the En-Bloc Resection. In: Soria F, Gontero P. (eds) *Treating Urothelial Bladder Cancer*. pp 19-29. Springer, Cham. Aug 2018. <https://link.springer.com/book/10.1007/978-3-319-78559-2#editorsandaffiliations>
95. Hurle R, Maccagnano C, Forni G. Active surveillance for low-risk non-muscle invasive bladder cancer. In: Soria F, Gontero P. (eds) *Treating Urothelial Bladder Cancer*. pp 19-29. Springer, Cham. Aug 2018. <https://link.springer.com/book/10.1007/978-3-319-78559-2#editorsandaffiliations>
96. Naselli A, Hurle R, Paparella S, et al. Role of Restaging Transurethral Resection for T1 Non-muscle invasive Bladder Cancer: A Systematic Review and Meta-analysis. *European Urology Focus*, Volume 4, Issue 4, Jul 2018, Pages 558-567. DOI:<https://doi.org/10.1016/j.euf.2016.12.011>
97. Vartolomei M, Lucarelli G, Russo GI, Francesco Cantiello F, Abu Farhan AR, Terracciano D, Cimmino A, Di Stasi S, Musi G, Rodolfo Hurle R, et al. An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. *World Journal of Urology* volume 37, pages507–514 (2019), Jul 2018. DOI:<https://doi.org/10.1007/s00345-018-2397-1>
98. Hurle R, Buffi N, Lista G, et al. Long-term outcomes of high-grade T1 bladder cancer treated with intravesical bacillus Calmette-Guérin: experience of a single center. *Minerva Urologica e Nefrologica = The Italian Journal of Urology and Nephrology*, Jul 2018, 70(5):501-508. DOI:<https://doi.org/10.23736/s0393-2249.18.03042-4>
99. Lopci E, Saita A, Lazzeri M, Lughezzani G, Colombo P, Buffi NM, Hurle R, et al. 68Ga-PSMA Positron Emission Tomography/Computerized Tomography for Primary Diagnosis of Prostate Cancer in Men with Contraindications to or Negative Multiparametric Magnetic Resonance Imaging: A Prospective Observational Study. *The Journal of Urology*, Volume 200 Issue 1, Jul 2018, Pages: 95-103. DOI:<https://doi.org/10.1016/j.juro.2018.01.079>
100. Ferro M, Vartolomei MD, Cantiello F, Lucarelli G, Di Stasi SM, Hurle R, et al. High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study. *Urologia Internationalis*, Jul 2018, Vol.101, No.1. DOI:<https://doi.org/10.1159/000490765>
101. Lazzeri M, Lopci E, Lughezzani G, Casale P, Hurle R, et al. MP20-14 “Positive prostate 68GAPSA-PET/CT correlates with detection of CD45-/PSMA+ non-sperm epithelial cells obtained by liquid biopsy of seminal fluid in patients with prostate cancer (PCA).” *The Journal of Urology*, Vol. 199, No. 4S, Supplement, May 2018. DOI:<https://doi.org/10.1016/j.juro.2018.02.684>
102. Saita A, Lazzeri M, Buffi NM, Casale P, Hurle R, et al. PD35-12 “Retrograde intrarenal surgery - single hand (RIRS-SH) by new a semi-flexible ureteroscopy for medium size (1.5 to 2 cm) renal stone: preliminary results from a single centre stage 2a study.” *The Journal of Urology*, Vol 199 Issue 4S, Apr 2018, Page: e725-e726. DOI:<https://doi.org/10.1016/j.juro.2018.02.1723>
103. Lughezzani G, Maffei D, Lazzeri M, Cardone P, Lista G, Colombo P, Casale P, Saita A, Buffi N, Hurle R, et al MP82-18 Assessing the diagnostic accuracy of micro-ultrasound for the detection of clinically significant prostate cancer: results from a single-institutional preliminary experience. *The Journal of Urology*, Vol 199, Issue 4S, Apr 2018, Page: e1113. DOI:<https://doi.org/10.1016/j.juro.2018.02.2746>
104. Saita A, Casale P, Lazzeri M, Buffi NM, Hurle R, et al. MP55-17 “New conception for flexor view deflecting endoscopic system use, in order to improve stone free rate (SFR) after RIRS: preliminary results from a single centre stage 2a study.” *The Journal of Urology*, Vol199(4): e754, Apr 2018. DOI:<http://dx.doi.org/10.1016/j.juro.2018.02.1788>
105. Naspro R, Manica M, Hurle R, et al. MP83-14 Adherence to good quality transurethral resection of the bladder (GQ-WLTURBT) markers in high volume centres: results from 4 north italian institutions. *The Journal of Urology*, Vol 199, Issue 4S, Apr 2018, Page: e1121. DOI:<https://doi.org/10.1016/j.juro.2018.02.2762>
106. Naspro R, Manica M, Rodolfo Hurle R, et al. MP08-15 “Correlation between surgeon’s experience and pathological and oncological outcomes after transurethral resection of the bladder: Results from

- a multicentric retrospective study." Volume 199, Issue 4S, Apr 2018, Page: e101-e102.
DOI:<https://doi.org/10.1016/j.juro.2018.02.320>
107. Lista G, Lughezzani G, Lazzeri M, Maffei D, Cardone P, Colombo P, Buffi NM, Hurle R, et al. MP77-05 "Urologist learning curve has an impact on increasing probability of clinically significant cancer detection rate at MPMRI-trus fusion target biopsy: a prospective study in a single high volume institution". Journal of urology, Vol 199 4S, Supplement, Apr 2018.
DOI:<https://doi.org/10.1016/j.juro.2018.02.2593>
 108. Grizzi F, Mandressi A, Colombo P, Melegari S, Justick M, Bozzini C, Seveso M, De Francmcesco O, Buffi NM, Lughezzani G, Lazzeri M, Hurle R. et al. MP64-07 "Vascular hurst index in non-tumoral biopsy cores as potential histopathological parameter to select patients with hidden prostate cancer." Journal of urology, Vol 199 4S, Supplement, Apr 2018.
DOI:<https://doi.org/10.1016/j.juro.2018.02.2052>
 109. Lazzeri M, Lopci E, Lughezzani G, Buffi NM, Casale P, Hurle R, et al. PD06-11 "68ga-psma pet/ct for primary diagnosis of prostate cancer in men with contraindications to or negative MRI: a prospective observational study." Journal of urology, Vol 199 4S, Supplement, Apr 2018.
DOI:<https://doi.org/10.1016/j.juro.2018.02.431>
 110. Lazzeri M, Colombo F, Chiereghin C, Buffi NM, Casale P, Hurle R, et al. PD06-10 Liquid biopsy by prostate-derived tumor cells enriched from seminal fluid (SF): the semen prostate cancer tumor elements (spectre) project. Journal of urology, Vol 199, Issue 4S, Apr 2018, Page: e154-e155.
DOI:<https://doi.org/10.1016/j.juro.2018.02.430>
 111. Grizzi F, Mandressi A, Colombo P, Melegari S, Justick M, Bozzini C, Seveso M, De Francmcesco O, Buffi NM, Lughezzani G, Lazzeri M, Hurle R. et al. MP64-07 "Vascular hurst index in non-tumoral biopsy cores as potential histopathological parameter to select patients with hidden prostate cancer." Journal of urology, Vol 199 4S, Supplement, Apr 2018.
DOI:<https://doi.org/10.1016/j.juro.2018.02.2052>
 112. Lista G, Lughezzani G, Buffi N, Peschechera R, Lazzeri M, Casale P, Hurle R, et al. Early versus standard catheter removal after complete anatomical reconstruction during robot-assisted radical prostatectomy: Results from a prospective single-institutional randomized trial (RIPRECA). European Urology Supplements 17(2): e1905. Mar 2018. DOI:[http://dx.doi.org/10.1016/S1569-9056\(18\)32312-1](http://dx.doi.org/10.1016/S1569-9056(18)32312-1)
 113. Hurle R, Saita A, Lazzeri M, et al. V54 - "En bloc" thulium laser resection of NMIBC: Technique and preliminary results. European Urology Supplements, Vol 17, Issue 2, Mar 2018, Page e1966.
DOI:[https://doi.org/10.1016/S1569-9056\(18\)32369-8](https://doi.org/10.1016/S1569-9056(18)32369-8)
 114. Hurle R, Lazzeri M, Saita A, et al. 737 - Long-term follow-up in high risk non muscle invasive bladder cancer (NMIBC) "en-bloc" resection. European Urology Supplements, Vol 17, Issue 2, Mar 2018, Page e1063. DOI:[https://doi.org/10.1016/S1569-9056\(18\)31572-0](https://doi.org/10.1016/S1569-9056(18)31572-0)
 115. Hurle R, Lazzeri M, Vanni E, et al. Active Surveillance for Low Risk Nonmuscle Invasive Bladder Cancer: A Confirmatory and Resource Consumption Study from the BIAS Project. The Journal of Urology, Volume 199 Issue 2, February 2018 Pages: 401-406.
DOI:<https://doi.org/10.1016/j.juro.2017.08.091>
 116. Lopci E, Lazzeri M, Lughezzani G, Colombo P, Buffi NM, Castello A, Lo Iacono N, Hurle R, et al. Primary diagnosis of prostate cancer: potential role of Ga-68-Prostate Specific Membrane Antigen PET/CT. European Journal of nuclear medicine and molecular imaging, 2018, abstract Vol 45 page 519. <http://hdl.handle.net/11699/2166>
 117. Badenchini F, Alvisi, Battaglia M, Enrico B, Borghesi M, Cicchetti G, Colombo P, Colecchia M, Cusumano G, Da Pozzo L, Ditunno P, Diazz D, Fiorentino M, Frego E, Gallucci M, Giliberti A, Guazzoni G, Hurle R, et al. Widespread use of protocol-based active surveillance in prostate cancer: the SluRO PRIAS ITA experience. Anticancer Research, 2018, Vol 38, Pages 2536-2538.
<http://hdl.handle.net/11699/9647>
 118. Hurle R, Lazzeri M, Vanni E, Lughezzani G, Buffi N, Casale P, Saita A, Morengi E, Forni G, Cardone P, Lista G, Colombo P, Peschechera R, Pasini L, Zandegiacomo S, Benetti A, Maffei D,

- Vavassori I, Guazzoni G. Active Surveillance for Low Risk Non muscle Invasive Bladder Cancer: A Confirmatory and Resource Consumption Study from the BIAS Project. THE JOURNAL OF UROLOGY, 2018 Feb;199(2): 401-406. DOI:<https://doi.org/10.1016/j.juro.2017.08.091>
119. Patriarca C, Hurle R, Colombo P, Colecchia M, Freschi M, Conti G, Petracco G, Colombo R (2018). In reply to: Lawless et al. Stalk versus base invasion in pT1 papillary cancers of the bladder: improved substaging system predicting the risk of progression. Histopathology, 2018 Jan;72(2):361-362. DOI:<https://doi.org/10.1111/his.13374>
 120. Colombo R, Hurle R, Moschini M, et al. Feasibility and Clinical Roles of Different Substaging Systems at First and Second Transurethral Resection in Patients with T1 High-Grade Bladder Cancer. European Urology Focus, Volume 4, Issue 1, January 2018, Pages 87-93. DOI:<https://doi.org/10.1016/j.euf.2016.06.004>
 121. Badenchini F, Alvisi MF, Battaglia M, Bollito E, Borghesi M, Cicchetti G, Colombo P, Colecchia M, Cusumano G, Da Pozzo L, Ditunno P, Diazi D, Fiorentino M, Frego E, Gallucci M, Giliberti A, Guazzoni G, Hurle R, et al. Evaluation of compliance of patients with prostate cancer with active surveillance protocol in a large multi-centric italian population. Anticancer Research, Vol 37(4), Page2113-2115, 2017. <http://hdl.handle.net/11699/7887>
 122. Lazzeri M, Lopci E, Lughezzani G, Colombo P, Casale P, Hurle R, et al. Targeted 11C–choline PET-CT/TRUS software fusion-guided prostate biopsy in men with persistently elevated PSA and negative mpMRI after previous negative biopsy. European Journal of Hybrid Imaging, volume 1, Article number: 9, Nov 2017. DOI:<https://doi.org/10.1186/s41824-017-0011-1>
 123. Buffi NM, Lughezzani G, Hurle R, et al. Robot-assisted Surgery for Benign Ureteral Strictures: Experience and Outcomes from Four Tertiary Care Institutions. European Urology, Volume 71, Issue 6, Jun 2017, Pages 945-951. DOI:<https://doi.org/10.1016/j.eururo.2016.07.022>
 124. Lazzeri M, Lughezzani G, Buffi NM, Lista G, Casale P, Hurle R, et al. MP28-04 sensitivity of [-2] propSA (p2psa) measurements for prediction of biochemical recurrence (bcr) in men after radical prostatectomy: a 3-years prospective cohort study." Journal of urology, Vol Volume 197, Issue 4S, Apr 2017, Page: e339. DOI:<https://doi.org/10.1016/j.juro.2017.02.817>
 125. Lopci E, Lazzeri M, Lughezzani G, Buffi NM, Casale P, Hurle R, et al. MP77-03 Targeted 11C-CHOLINE PET/CT/TRUS software fusion-guided prostate biopsy has in men with persistently elevated psa after previous negative biopsy. Journal of urology, Vol 197, Issue 4S, Apr 2017, Page: e1022. DOI:<https://doi.org/10.1016/j.juro.2017.02.2111>
 126. Lista G, Lughezzani G, Lazzeri M, Bini V, Hurle R, et al. MP03-18 "Absence of learning curve impact may let MRI-TRUS fusion guided biopsy up for early diagnosis of prostate cancer." Journal of urology, Vol 197 4S, Supplement, Apr 2017. DOI:<https://doi.org/10.1016/j.juro.2017.02.135>
 127. Hurle R, Lazzeri M, Lughezzani G, et al. PD19-01 "Active surveillance for non-muscle invasive bladder cancer (NMIBC): result from bladder cancer italian active surveillance (BIAS) project". Journal of urology, Vol 197 4S, Supplement, Apr 2017. DOI:<https://doi.org/10.1016/j.juro.2017.02.874>
 128. Hurle R, Lazzeri M, Saita A, Forni G, Buffi N, Casale P, Lughezzani G, Pescechera R, Pasini L, Zandegiacomo S, Benetti A, Lista G, Maffei D, Cardone P, Colombo P, Guazzoni G, G. Lista, D. Maffei, P. Cardone, P. Colombo, G. Guazzoni R. Hurle, M. Lazzeri, A. Saita, G. Forni, N. Buffi, P. Casale, G. Lughezzani, R. Pescechera, L. Pasini, S. Zandegiacomo, A. Benetti, G. Lista, D. Maffei, P. Cardone, P. Colombo, G. Guazzoni (2017). Active surveillance for non-muscle invasive bladder cancer (NMIBC): Result from bladder cancer Italian active surveillance (BIAS) project. European Urology Supplements, Vol 16, Issue 3, Mar 2017, Pages e1137-e1138. DOI:[https://doi.org/10.1016/S1569-9056\(17\)30710-8](https://doi.org/10.1016/S1569-9056(17)30710-8)
 129. Hurle R, Lazzeri M, Colombo P, Buffi N, Morengi E, Pescechera R, Castaldo L, Pasini L, Casale P, Seveso M, Zandegiacomo S, Taverna G, Benetti A, Lughezzani G, Fiorini G, Guazzoni GA. "En Bloc" Resection of Nonmuscle Invasive Bladder Cancer: A Prospective Single-center Study. UROLOGY, vol. 90, p. 126-13, Apr 2016. DOI:<https://doi.org/10.1016/j.urology.2016.01.004>

130. Hurle R, Lazzeri M, Buffi NM, et al. En bloc resection of bladder tumours (ERBT): multivariable analysis for prediction of recurrence at mid-term follow-up. *The Journal of Urology*, 195(4): e287-e288, Apr 2016. DOI:<http://dx.doi.org/10.1016/j.juro.2016.02.842>
131. Kramer MW, Altieri V, Hurle R, Lusuardi L, Merseburger AS, Rassweiler J. Current Evidence of Transurethral En-bloc Resection of Nonmuscle Invasive Bladder Cancer. *European Urology Focus*, 2017 Dec; 3(6):567-576. DOI:<https://doi.org/10.1016/j.euf.2016.12.004>
132. Buffi NM, Lughezzani G, Hurle R, Lazzeri M, Taverna G, Bozzini G, Bertolo R, et al. Robot-assisted surgery for benign ureteral stenosis: Experience and outcomes from four tertiary care institutions. *EUROPEAN UROLOGY. SUPPLEMENTS*, 2017 Jun; 71(6):945-951. DOI:<https://doi.org/10.1016/j.eururo.2016.07.022>
133. Lughezzani G, Buffi N, Lista G, Maffei D, Forni G, Fossati N, Larcher A, Lazzeri M, Saita A, Casale P, Hurle R, et al. MP49-13 "Comparative analysis of the outcomes of transperitoneal and retroperitoneal robot assisted partial nephrectomy: results from a multi-institutional high-volume centers experience." *The Journal of Urology*, Vol. 197, No. 4S, Supplement, May 2017. DOI:<https://doi.org/10.1016/j.juro.2017.02.1515>
134. Hurle R, Pasini L, Lazzeri M, Colombo P, Buffi N, Lughezzani G, Casale P, Morengi E, Pescechera R, Zandegiacomo S, Benetti A, Saita A, Cardone P, Guazzoni G (2016). Active surveillance for low-risk non-muscle-invasive bladder cancer: mid-term results from the Bladder cancer Italian Active Surveillance (BIAS) project. *BJU INTERNATIONAL*, 2016 Dec; 118(6):935-939. DOI:<https://doi.org/10.1111/bju.13536>
135. Hurle R, Roberto Pescechera R, Nicolò Maria Buffi NM, et al. Impact of a teaching program on outcome quality of white light transurethral resection for bladder tumor: A cohort study. *Journal of Solid Tumors*, Jul 2016, Vol. 6, No. 2. DOI:<https://doi.org/10.5430/jst.v6n2p56>
136. Lughezzani G, Lazzeri M, Hurle R, et al. MP02-01 "Clinical utility of PHI (prostate health index) in men with tPSA>10 ng/ml. Results from a multicentric european study". *The Journal of Urology*, Volume 195 Issue 4S. Apr 2016, Page: e9. DOI:<https://doi.org/10.1016/j.juro.2016.02.1873>
137. Lazzeri M, Hurle R, Casale P, Buffi N, Lughezzani G, Fiorini G, Pescechera R, Pasini L, Zandegiacomo S, Benetti A, Taverna G, Guazzoni G, Barbagli G. Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans: an update on the evidence. *Therapeutic Advances in Urology*, 2016 Apr; 8(2):91-9. DOI:<https://doi.org/10.1177/1756287215621234>
138. Lazzeri M, Lughezzani G, Haese A, McNicholas T, de la Taille A, Buffi NM, Cardone P, Hurle R, Casale P, Bini V, Redorta JP, Graefen M, Guazzoni G. Clinical performance of prostate health index in men with tPSA>10ng/ml: Results from a multicentric European study. *Urologic Oncology*, 2016 Sep; 34(9):415.e13-9. DOI:<https://doi.org/10.1016/j.urolonc.2016.04.003>
139. Lazzeri M, Lughezzani G, Buffi N, Casale P, Hurle R, Fiorini G, Pescechera R, Pasini L, Zandegiacomo S, Balzarini L, Mrakic F, Bini V, Guazzoni G. MP16-07 "Should we continue to biopsy men with PI-RADS III after previous negative biopsy?" *The Journal of Urology*, Volume 195 Issue 4S, Apr 2016, Page: e163. DOI:<https://doi.org/10.1016/j.juro.2016.02.2572>
140. Patriarca C, Hurle R, Moschini M, et al. Re: Usefulness of pT1 Substaging in Papillary Urothelial Bladder Carcinoma. *The Journal of Urology*, Jun 2016, vol. 196 (3), p. 689-698, DOI:<http://dx.doi.org/10.1016/j.juro.2016.06.036>
141. Patriarca C, Hurle R, Moschini M, et al. Usefulness of pT1 substaging in papillary urothelial bladder carcinoma. *Diagnostic Pathology*, Jan 2016, 11(1). DOI:<https://diagnosticpathology.biomedcentral.com/articles/10.1186/s13000-016-0466-6>
142. Buffi NM, Lughezzani G, Lazzeri M, Casale P, Fiorini G, Hurle R, Taverna GL, Guazzoni G. [The added value of robotic surgery]. *Urologia*, 2015 Oct;82 Suppl 1:S11-3. DOI:<https://doi.org/10.5301/uro.5000149>

143. Badenchini F, Alvisi MF, Conti G, Gallucci M, Martorana G, Diazzì D, Sanseverino R, Napodano G, Frego E, Tanello M, Guazzoni G, Hurle R, Pasini L, Turci A, Cicchetti G, Ditunno P, Bollito E, Colecchia M, Fiorentino M, Montironi R, Patriarca C, Raspollini MR, Sentinelli S, Rancati T, Magnani T, Bangma C, Valdagni R. SIUrO-PRIAS-ITA Project: five year experience on active surveillance. *Anticancer research*, Jun 2015, Vol 35; 3634-3636.
144. Ferro M, De Cobelli O, Buonerba C, Di Lorenzo G, Capece M, Bruzzese D, Autorino R, Bottero D, Cioffi A, Matei DV, Caraglia M, Borghesi M, De Berardinis E, Busetto GM, Giovannone R, Lucarelli G, Ditunno P, Perdonà S, Bove P, Castaldo L, Hurle R, Musi G, Brescia A, Olivieri M, Cimmino A, Altieri V, Damiano R, Cantiello F, Serretta V, De Placido S, Mirone V, Sonpavde G, Terracciano D. Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy: A Multicenter Experience. *Medicine*, 2015 Oct; 94(42): e1861. DOI:<https://doi.org/10.1097/md.0000000000001861>
145. Hurle R, Castaldo L, Taverna G, et al. MP26-05 "Active Surveillance Program in Recurrent NMIBC." *The Journal of Urology*, Volume 193 Issue 4S, Apr 2015, Page: e295. DOI:<https://doi.org/10.1016/j.juro.2015.02.1127>
146. Hurle R, Patriarca C, Pasini I, et al. PD41-02 "A new proposal for T1, high grade (HG) bladder cancer (BCA) micro-staging definition. *The Journal of Urology*, Vol. 193, No. 4S, Supplement, May 2015, p. E840. DOI:<http://dx.doi.org/10.1016/j.juro.2015.02.2410>
147. Hurle R, C. Patriarca, L. Pasini, P.G. Colombo, L. Castaldo, M. Moschini, L. Ferrari, M. Maffezzini, et al. 1045-A new proposal for t1, high grade bladder cancer micro-staging definition. *European Urology Supplements*, Vol 14, Issue 2, Apr 2015, Pages e1045-e1045a. DOI:[https://doi.org/10.1016/S1569-9056\(15\)61033-8](https://doi.org/10.1016/S1569-9056(15)61033-8)
148. Hurle R, Patriarca C, Pasini L, Colombo PG, Castaldo L, Moschini M, Ferrari L, Maffezzini M, Colecchia M, Magnani T, Freschi M, Capogrosso P, Conti G, Colombo R. A new proposal for t1, high grade bladder cancer micro-staging definition. *Anticancer Research*, vol. 35, p. 3662, ISSN: 0250-7005
149. Kramer MW, Martov A, Baykov N, Klein J, Rassweiler JJ, Lusuadi L, Janetschek G, Hurle R, et al. (2015). Laser versus electrical en bloc resection of bladder tumors: results of a european multicenter study (EBRUC). *Journal of Clinical Oncology*, vol. 33, ISSN: 0732-183X
150. Kramer MW, Rassweiler JJ, Klein J, Martov A, Baykov N, Hurle R, et al (2015). Safety, efficacy, and 12-months recurrence rate of laser vs. electrical en bloc resection of urothelium carcinoma of the bladder: results of the ebruc trial. *The Journal of Urology*, vol. 193, p. E294, ISSN: 0022-5347
151. M.W. Kramer, A. Martov, N. Baykov, J. Klein, J. Rassweiler, L. Lusuadi, G. Janetschek, Hurle R, and others (2015). En bloc resection of urothelium carcinoma of the bladder (EBRUC): A European multi-center study to compare safety, efficacy and 12-months recurrence rate of laser and electrical en bloc TURBT. *European Urology. Supplements*, ISSN: 1569-905
152. Kramer MW, Rassweiler JJ, Klein J, Martov A, Baykov N, Lusuadi L, Janetschek G, Hurle R, Wolters M, Abbas M, von Klot CA, Leitenberger A, Riedl M, Nagele U, Merseburger AS, Kuczyk MA, Babjuk M, Herrmann TR (2015). En bloc resection of urothelium carcinoma of the bladder (EBRUC): A European multicenter study to compare safety, efficacy, and outcome of laser and electrical en bloc transurethral resection of bladder tumor. *World Journal of Urology*, vol. 33, p. 1937-1943, ISSN: 0724-4983, DOI:<https://doi.org/10.1007/s00345-015-1568-6>
153. Lughezzani G, Lazzeri M, Buffi NM, Abrate A, Mistretta FA, Hurle R, Pasini L, Castaldo L, Zandegiacomo De Zorzi S, Pescechera R, Fiorini G, Taverna G, Casale P, Guazzoni G. (2015). Preoperative prostate health index is an independent predictor of early biochemical recurrence after radical prostatectomy: Results from a prospective single-center study. *UROLOGIC ONCOLOGY*, vol. 33, p. 7-14, ISSN: 1078-1439, DOI:<https://doi.org/10.1016/j.urolonc.2015.05.007>
154. Magnani T, Labianca R, Baier S, Baldazzi V, Barni S, Baron C, Bassi P, Basso U, Beatrice V, Bellardita L, Bertolotto F, Bombardieri E, Bortolus R, Bracarda S, Brandes A, Buli P, Bunkheila F, Caffo O, Cagna E, Cazzaniga LF, Ceresoli GL, Colosini G, Corti L, D'agostino G, Da Pozzo L, De Angelis M, Del Duca M, DiGrazia A, Divan C, Facchini G, Fellin G, Ferraù F, Fragala E, Fratino L, Frezza G, Gabriele P, Gabrielloni G, Garbeglio A, Garibaldi E, Giordano M, Graiff C, Guttilla A,

- Hurle R, Kçlli M, Lapini A, Lastrucci L, Leoni, M, Livi L, Lukas P, Mantini G, Marafioti L, Martorana G, Mattioli R, Micheli E, Migliosi G, Morgia G, Muto G, Muto P, Ortega C, Orsatti M, Palazzo S, Perdonà S, Pinto F, Prati V, Procopio G, Pycha A, Repetto L, Sarti E, Scarzello G, Schiavina R, Schinzari G, Stagni S, Tanello M, Valentini, Vavassori I, Vavassori V, Ventura F, Villa S, Vitali E, Voce S, Zagone L V, Zattoni F, Zucali PA, Valdagni R, Conti, G (2015). towards the multidisciplinary management of prostate cancer patients: the perstep project experience. *Anticancer Research*, vol. 35, p. 3659-3661, ISSN: 0250-7005
155. Racioppi M, Salmaso L, Brombin C, Arboretti R, D'Agostino D, Colombo R, Serretta V, Brausi M, Casetta G, Gontero P, Hurle R, Tenaglia R, Altieri V, Bartoletti R, Maffezzini M, Siracusano S, Morgia G, Bassi PF (2015). The clinical use of statistical permutation test methodology: a tool for identifying predictive variables of outcome. *UROLOGY INTERNATIONAL*, vol. 94, p. 262-269, ISSN: 1352-9544, DOI: <https://doi.org/10.1159/000365292>
 156. Seveso M, Castaldo L, Hurle R, Taverna G, Lazzeri M, Pasini L, Buffi NM, Lughezzani G, Casale P, Zandegiacomo De Zorzi S, Benetti A, Guazzoni GF (2015). Laparoscopic partial nephrectomy after previous ipsilateral renal procedures. *Anticancer Research*, vol. 35, p. 3708, ISSN: 0250-7005
 157. Simone G, Bianchi M, Giannarelli D, Daneshmand S, Papalia R, Ferriero M, Guaglianone S, Sentinelli S, Colombo R, Montorsi F, Collura D, Muto G, Novara G, Hurle R, Rink M, Fisch M, Abol-Enein H, Miranda G, Desai M, Gill I, Gallucci M (2015). Development and external validation of nomograms predicting disease-free and cancer-specific survival after radical cystectomy. *World Journal of Urology*, vol. 33, p. 1419-1428, ISSN: 0724-4983, DOI: 10.1007/s00345-014-1465-4.
 158. Taverna G, Tidu L, Grizzi F, Torri V, Mandressi A, Sardella P, La Torre G, Cocciolone G, Seveso M, Giusti G, Hurle R, Santoro A, Graziotti P (2015). Olfactory system of highly trained dogs detects prostate cancer in urine samples. *The Journal of Urology*, vol. 193, p. 1382-1387, ISSN: 0022-5347, DOI: <https://doi.org/10.1016/j.juro.2014.09.099>
 159. Bottero D, Ferro M, Matei D, Cioffi A, Musi G, Melegari S, Castaldo L, Hurle R, Graziotti P, de Cobelli O (2014). Virtue® Male Sling for Stress Incontinence: Single Arm, Non-Randomized, Single-Center Clinical Study and 1-Year Follow-Up - A Series of 29 Patients. *UROLOGY*, ISSN: 0090-4295
 160. G. Taverna, L. Tidu, F. Grizzi, A. Mandressi, M. Seveso, G. Giusti, A. Benetti, Hurle R, and others (2014). Prostate cancer urine detection through highly-trained dogs olfactory system: A real clinical opportunity. *European Urology. Supplements*, ISSN: 1569-9056
 161. Hurle R, De Zorzi SZ, Castaldo L, Pasini L, Taverna G, Puppo P, Graziotti P (2014). Impact of a dedicated teaching program on quality outcomes of white light TURBT. *The Journal of Urology*, vol. 191, p. E692, ISSN: 0022-5347
 162. Hurle R, De Zorzi SZ, Castaldo L, Pasini L, Taverna G, Puppo P, Naselli A, Graziotti P (2014). Collins loop en bloc resection (CLEBR) for accurate staging of primary non muscle invasive bladder cancer: early experience. *The Journal of Urology*, vol. 191, p. E693, ISSN: 0022-5347
 163. Hurle R, Castaldo L, Pasini L, Seveso M, Taverna G, Ferro M, Bottero D, Puppo P, de Cobelli O, Graziotti P (2014). Active Surveillance Protocol NMIBC. *Urology*, ISSN: 0090-4295
 164. Hurle R, Castaldo L, Pasini L, Seveso M, Taverna G, Ferro M, Bottero D, Puppo P, de Cobelli O, Graziotti P (2014). Collins Loop En Bloc Resection (CLEBR) for Accurate Staging of Primary Non-Muscle Invasive Bladder Cancer: Early Experience. *UROLOGY*, ISSN: 0090-4295
 165. Hurle R, Castaldo L, Pasini L, Seveso M, Taverna G, Ferro M, Naselli A, Bottero D, Puppo P, de Cobelli O, Graziotti P (2014). Impact of a Dedicated Teaching Program on Quality Outcomes of White Light TURBT. *Urology*, ISSN: 0090-4295
 166. Hurle R, Castaldo L, Taverna G, Pasini L, Ferro M, Bottero D, Naselli A, Puppo P, de Cobelli O, Graziotti P (2014). Is Second-Transurethral Resection Really Needed for T1 Bladder Cancer? Systematic Review, Metaanalysis of the Literature and of a Contemporary Cases Series. *UROLOGY*, ISSN: 0090-4295
 167. Simone G, Bianchi M, Giannarelli D, Papalia R, Ferriero M, Guaglianone S, Colombo R, Briganti A, Montosi F, Collura D, Muto G, Novara G, Hurle R, Rink M, Fisch M, Abol-Enein H, Ghoneim M,

- Miranda G, Daneshmand S, Desai M, Gill I, Gallucci M (2014). Development and external validation of nomograms predicting disease-free and cancer specific survival after radical cystectomy. *The Journal of Urology*, vol. 191, p. E559-E560, ISSN: 0022-5347
168. Taverna G, Tidu L, Grizzi F, Giusti G, Seveso M, Benetti A, Hurle R, Zandegiacomo S, Pasini L, Mandressi A, Graziotti P (2014). Prostate cancer urine detection through highly-trained dogs' olfactory system: a real clinical opportunity. *The Journal of Urology*, vol. 191, p. E546, ISSN: 0022-5347
169. Taverna G, Seveso M, Giusti G, Hurle R, Graziotti P, Stifter S, Chiriva-Internati M, Grizzi F (2014). Senescent remodeling of the innate and adaptive immune system in the elderly men with prostate cancer. *Current Gerontology And Geriatrics Research*, ISSN: 1687-7071, doi:<https://doi.org/10.1155/2014/478126>
170. Alongi F, Iftode C, Arcangeli S, Liardo R, Hurle R, Comito T, Villa E, Tozzi A, Navarra P, Mancosu P, Tomatis S, Taverna G, Graziotti P, Scorsetti M (2013). Five fractions linac based sbrrt for low-intermediate risk prostate cancer: preliminary report of a phase II study with flattening filter free delivery and space oar. *Anticancer Research*, vol. 33, p. 2259, ISSN: 0250-7005
171. Montironi R, Bartels PH, DeCensi A, Puntoni M, Hurle R, Decobelli O, Carmignani G, Mazzucchelli R, Bartels HG, Alberts DS, Maffezzini M (2013). A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide vs. placebo in men with prostate cancer. Efficacy monitored by karyometry. *Urologic Oncology*, vol. 31, p. 557-565, ISSN: 1078-1439, doi:<https://doi.org/10.1016/j.urolonc.2011.02.024>
172. Taverna G, Magnoni P, Giusti G, Seveso M, Benetti A, Hurle R, Colombo P, Minuti F, Grizzi F, Graziotti P (2013). Impact of Real-Time Elastography versus Systematic Prostate Biopsy Method on Cancer Detection Rate in Men with a Serum Prostate-Specific Antigen between 2.5 and 10 ng/mL. *Isrn Oncology*, ISSN: 2090-5661, DOI:<http://dx.doi.org/10.1155/2013/584672>
173. Taverna G, Giusti G, Seveso M, Hurle R, Colombo P, Stifter S, Grizzi F (2013). Mast cells as a potential prognostic marker in prostate cancer. *Disease Markers*, vol. 35, p. 711-720, ISSN: 0278-0240, DOI:<https://doi.org/10.1155/2013/478303>
174. Naselli A, Hurle R, Puppo P (2012). The role of narrow-band imaging in the management of non-muscle-invasive bladder cancer. *Expert Review of Anticancer Therapy*, vol. 12, p. 1523-1528, ISSN: 1473-7140, DOI:<https://doi.org/10.1586/era.12.137>
175. Spatafora S, Casarico A, Fandella A, Galetti C, Hurle R, Mazzini E, Niro C, Perachino M, Sanseverino R, Pappagallo GL, for the AURO.it BPH Guidelines Committee (2012). Evidence-based guidelines for the treatment of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary from AURO.it. *Therapeutic Advances in Urology*, vol. 12, p. 1523-1528, ISSN: 1756-2872, DOI:<https://doi.org/10.1177%2F1756287212463112>
176. Bassi PF, Bongiovanni L, Racioppi M, Volpe A, D'Agostino D, Gardi M, F.E.B.U, G.I.S.Ca.V. Participants in the Gruppo Italiano Studio Carcinoma della Vescica (G.I.S.Ca.V.) Altieri V, Casetta G, Colombo R, Hurle R, Maffezzini M, Morgia G, Serretta V, Siracusano S (2011). Postoperative nomogram for invasive bladder cancer: does it really work? A multicenter cohort study. *Urologic Oncology*, vol. 29, p. 698-702, ISSN: 1078-1439, DOI:<https://doi.org/10.1016/j.urolonc.2009.08.010>
177. Bassi PF, Racioppi M, Salmaso L, Brombin C, Volpe A, D'agostino D, Bassi M, Altieri V, Bartoletti R, Brausi M, Casetta G, Colombo R, Gontero P, Hurle R, Maffezzini M, Morgia G, Serretta V, Siracusano S, (2010). NPC- A newer revolutionary test for evaluation of clinical series bladder cancer. *Anticancer Research*, vol. 30, p. 1445, ISSN: 0250-7005
178. Hurle R, Naspro R (2010). Pelvic lymphadenectomy during radical cystectomy: a review of the literature. *Surgical Oncology*, vol. 19, p. 208-220, ISSN: 0960-7404, DOI:<https://doi.org/10.1016/j.suronc.2009.05.004>
179. Maffezzini M, Campodonico F, Hurle R, De Cobelli O, Carmignani G, Montironi R (2010). Ample variability of prostatic biopsy sampling in patients with clinically intracapsular disease. A comparison

of biopsies at diagnosis and repeat biopsy on the surgical specimen. *Anticancer Research*, vol. 30, p. 1494, ISSN: 0250-7005

180. Maffezzini M, Campodonico F, Puntoni M, Hurle R, Decobelli O, Carmignani G, Montironi R, Bartels H, Descensi A (2010). Effects of minimal androgen exposure on prostate cancer, PIN and normal prostatic tissue. Results of a randomized double blind, placebo-controlled, pre-surgical trial of finasteride versus flutamide: implications for chemoprevention. *Anticancer Research*, vol. 30, p. 1493-1494, ISSN: 0250-7005
181. Mazzoleni F, Albo G, Verweij F, Botteri E, Detti S, Colombo R, Spasciani R, Hurle R, De Cobelli O, (2010). Thermo-chemotherapy for superficial transitional cell carcinoma of the bladder. Results of a multi centric clinical study: "Synergo Lombradia". *Anticancer Research*, vol. 30, p. 1538-1539, ISSN: 0250-7005
182. Vavassori I, Valenti S, Naspro R, Vismara A, Dell'Acqua V, Manzetti A, Hurle R (2008). Three-year outcome following holmium laser enucleation of the prostate combined with mechanical morcellation in 330 consecutive patients. *European Urology*, vol. 53, p. 599-604, ISSN: 0302-2838, DOI:<https://doi.org/10.1016/j.eururo.2007.10.059>
183. Ivano Vavassori, Sergio Valenti, Richard Naspro, Alberto Vismara, Vincenzo dell'Acqua, Alberto Manzetti, Hurle R (2007). Three-Year Outcome following Holmium Laser Enucleation of the Prostate Combined with Mechanical Morcellation in 330 Consecutive Patients. *European Urology, Supplements*, ISSN: 1569-9056
184. Vavassori I, Vismara A, Hurle R, Manzetti A, Valenti S, Dell'acqua V, Naspro R (2007). Holmium laser enucleation of the prostate combined with mechanical morcellation: 3 years of follow up. *European Urology, Supplements*, vol. 6, p. 163, ISSN: 1569-9056
185. Briganti A, Naspro R, Gallina A, Salonia A, Vavassori I, Hurle R, Scattoni E, Rigatti P, Montorsi F (2006). Impact on sexual function of holmium laser enucleation versus transurethral resection of the prostate: results of a prospective, 2-center, randomized trial. *The Journal of Urology*, vol. 175, p. 1817-1821, ISSN: 0022-5347, DOI: [https://doi.org/10.1016/S0022-5347\(05\)00983-3](https://doi.org/10.1016/S0022-5347(05)00983-3)
186. Morabito F, Rossi R, Graziano ME, Ferrando U, Lancini V, Cretarola E, Conti G, Luporini AC, Muto G, Castelli E, D'Urso L, Razionale P, Lissoni G, Simone M, Francesca F, Sommariva M, Casu M, Hurle R (2006). Multicenter study on the use of gemcitabine to prevent recurrence of multiple-recurring superficial bladder tumors following intravesical antitubercular agents and/or BCG: evaluation of tolerance. *Archivio Italiano Di Urologia Andrologia*, vol. 78, p. 1-4, ISSN: 1124-3562
187. Hurle R, Poma R, Maffezzini M, Manzetti A, Piccinelli A, Taverna G, Bellavita P, Graziotti P (2004). A simple mathematical approach to calculate blood loss in radical prostatectomy. *Urologia Internationalis*, vol. 72, p. 135-139, ISSN: 1423-0399, DOI: <https://doi.org/10.1159/000075967>
188. Vavassori, Hurle R, S. Valenti, A. Manzetti, A. Vismara, O. Fenice (2004). Holmium laser enucleation of prostate combined with mechanical morcellation Italian experience. *European Urology. Supplements*, ISSN: 1569-9056
189. Vavassori I, Hurle R, Vismara A, Manzetti A, Valenti S (2004). Holmium laser enucleation of the prostate combined with mechanical morcellation: two years of experience with 196 patients. *Journal of Endourology*, vol. 18, p. 109-112, ISSN: 0892-7790, DOI:<https://doi.org/10.1089/089277904322836767>
190. Hurle R, Vavassori I, Piccinelli A (2002). holmium laser enucleation of the prostate combined with mechanical morcellation in 155 patients with benign prostatic hyperplasia. *European Urology. Supplements*, ISSN: 1569-9056
191. Hurle R, Vavassori I, Piccinelli A, Manzetti A, Valenti S, Vismara A (2002). Holmium laser enucleation of the prostate combined with mechanical morcellation in 155 patients with benign prostatic hyperplasia. *Urology*, vol. 60, p. 449-453, ISSN: 0090-4295, DOI:[https://doi.org/10.1016/s0090-4295\(02\)01812-5](https://doi.org/10.1016/s0090-4295(02)01812-5)

192. A Losa, Hurle R, A Manzetti, E Micheli (2000). Standard (81 mg) versus low (27 mg) dose of Connaught Bacillus Calmette-Guerin in high risk superficial bladder cancer patients: preliminary results. *Bju International*, ISSN: 1464-4096
193. Hurle R, A Manzetti, E Micheli (2000). Additional bacillus Calmette-Guerin Therapy for bladder tumor recurrence after previous successful BCG therapy. *Bju International*, ISSN: 1464-4096
194. Hurle R, A Manzetti, E Micheli (2000). Factors affecting recurrence and progression in superficial bladder tumor treated with bacillus Calmette-Guerin: nine-years follow-up of 193 consecutive patients. *Bju International*, ISSN: 1464-4096
195. Losa A, Hurle R, Lembo A (2000). Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. *The Journal of Urology*, vol. 163, p. 68-71, ISSN: 0022-5347, DOI: [https://doi.org/10.1016/S0022-5347\(05\)67974-8](https://doi.org/10.1016/S0022-5347(05)67974-8)
196. Hurle R, Losa A, Manzetti A, Lembo A (1999). Upper urinary tract tumors developing after treatment of superficial bladder cancer: 7-year follow-up of 591 consecutive patients. *Urology*, vol. 53, p. 1144-1148, ISSN: 0090-4295, DOI: [https://doi.org/10.1016/S0090-4295\(99\)00002-3](https://doi.org/10.1016/S0090-4295(99)00002-3)
197. Hurle R, Manzetti A, Losa A, Micheli E, Ranieri A, Chinaglia D, Lembo A (1999). Intravesical bacille Calmette-Guérin in Stage T1 grade 3 bladder cancer therapy: a 7-year follow-up. *Urology*, vol. 61, p. 220-226, ISSN: 0090-4295, DOI: [https://doi.org/10.1016/S0090-4295\(99\)00116-8](https://doi.org/10.1016/S0090-4295(99)00116-8)
198. Hurle R, Manzetti A, Losa A, Micheli E, Ranieri A, Chinaglia D, Lembo A (1998). Intravesical instillation of mitomycin-C in 242 patients with superficial bladder cancer at high risk of recurrence: long-term results. *Urologia Internationalis*, vol. 61, p. 220-226, ISSN: 0042-1138, DOI: <https://doi.org/10.1159/000030333>
199. Micheli E, Hurle R, Losa A, Chinaglia D, Ranieri A, Lembo A (1999). Primary actinomycosis of the urachus. *BJU International*, vol. 83, p. 144-145, ISSN: 1464-4096
200. Brausi M, Hurle R, Lemboa, Palladini PD (1998). Immunotherapy with bcg in high risk recurrent bladder cancer previously treated with multiple cycles of chemotherapy: long-term results. *ACTA Urologica Italica*, ISSN: 0394-2511
201. Hurle R, Losa A, Manzetti A, Lembo A (1998). Intravesical instillation of mitomycin C in 242 patients with superficial bladder cancer at high risk of recurrence: long term results. *British Journal of Urology*, vol. 80, p. 42, ISSN: 0007-1331
202. Hurle R, Losa A, Ranieri A, Lembo A (1998). Acid-fast bacilli persisting in the genitourinary tract 3 years after intravesical bacille Calmette-Guérin therapy for bladder carcinoma. *British Journal of Urology*, vol. 81, p. 496-497, ISSN: 0007-1331
203. Losa A, Hurle R, Manzetti A, Lembo A (1998). Low-dose bacillus Calmette-Guerin in therapy of bladder carcinoma in situ: long term results. *British Journal of Urology*, vol. 80, p. 40, ISSN: 0007-1331
204. A Ranieri, M Tura, Hurle R, A Lembo (1997). Management of ureteral calculi and DRG. *Urologia*, ISSN: 0391-5603
205. Cozzoli A, Belussi D, Pezzotti G, Zani D, Tralce L, Cancarini G, Ranieri A, Hurle R, Cosciani Cunico S, Lembo A. (1997). [Conservative therapy of renal parenchymal neoplasia. *Archivio Italiano Di Urologia Andrologia*, vol. 69, p. 109-115, ISSN: 1124-3562
206. M Brausi, Hurle R, A Lembo, P D Palladini (1997). Low dose BCG in patients with recurrent superficial bladder tumors previously treated with multiple cycles of chemotherapy or immunotherapy. *British Journal of Urology*, ISSN: 0007-1331
207. Micheli E, Hurle R, Ranieri A, Belussi D, Losa A, Chinaglia D, Lembo A (1997). Three cases of adrenal myelolipoma and review of the literature. *ACTA Urologica Italica*, ISSN: 0394-2511

208. Hurle R, Graziotti P, Ranieri A, Losa A, Micheli E, Lembo A (1996). T1G3 transitional cell carcinoma of the bladder: our experience with 44 patients treated with intravesical BCG after TUR. *Archivio Italiano Di Urologia Andrologia*, vol. 68, p. 13-16, ISSN: 1124-3562
209. Hurle R, Losa A, Ranieri A, Graziotti P, Lembo A (1996). Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy. *The Journal of Urology*, vol. 156, p. 1602-1605, ISSN: 0022-5347, DOI: [https://doi.org/10.1016/S0022-5347\(01\)65458-2](https://doi.org/10.1016/S0022-5347(01)65458-2)
210. Hurle R, Losa a, Ranieri Graziotti, P, Lembo a (1996). Low dose Bacillus Calmette-Guerin regimen in stage T1 grade 3 bladder cancer prophylaxis. *The Journal of Urology*, vol. 155, p. 553A, ISSN: 0022-5347
211. Graziotti P, Losa A, Hurle R, Lembo A (1995). Our current indications for radical prostatectomy. *Archivio Italiano Di Urologia Andrologia*, vol. 67, p. 191-193, ISSN: 1124-3562
212. Hurle R, Losa A, Ranieri A, Graziotti P, Lembo A (1995). Computed tomography for bladder tumor staging: it is reliable? *ACTA Urologica Italica*, ISSN: 0394-2511
213. Ranieri A, Hurle R, Micheli E, Tura M, Graziotti P, Lembo A (1995). Surgical treatment of benign prostatic hypertrophy: what and when TURP vs adenectomy. *Archivio Italiano Di Urologia Andrologia*, vol. 67, p. 71-74, ISSN: 1124-3562
214. Ranieri A, Micheli E, Graziotti P, Tura M, Hurle R, Romano C, Lembo A (1994). Nerve-sparing retroperitoneal lymph node dissection in patients with non-seminomatous testicular tumors at clinical stage 1. *Archivio Italiano Di Urologia Andrologia*, vol. 66, p. 15-18, ISSN: 1124-3562
215. Belussi D, Graziotti P, Romano C, Guizzetti C, Ranieri A, Giannone V, Tura M, Hurle R, Losa A, Giardina G, Lembo A (1993). Conservative therapy in parenchymal renal carcinoma: our experience of 47 cases. *ACTA Urologica Italica*, p. 53-54, ISSN: 0394-2511
216. Losa A, Graziotti P, Hurle R, Belussi D, Micheli E, Lembo A (1993). The role of PSA, histologic grading and transrectal ecography in staging prostatic carcinoma. *ACTA Urologica Italica*, p. 113-114, ISSN: 0394-2511
217. P Graziotti, V Giannone, A Ranieri, C Guizzetti, C Romano, A Losa, Hurle R, A Lembo (1993). Personal experience on internal urethrotomy. *Urologia*, ISSN: 0391-5603
218. Hurle R, Graziotti P, Ranieri A, Giannone V, Losa A, Belussi D, Piccinelli A, Micheli E, Lembo A (1992). 1987-1991: Cystoprostatectomy 151 patients. Orthotopic bladder replacement: 15 patients. Strictness of indication or excessive caution? *ACTA Urologica Italica*, p. 145-146, ISSN: 0394-2511
219. Losa A, Graziotti P, Romano C, Belussi D, Hurle R, Piccinelli A, Tura M, Lembo A (1992). Early and late complications of radical prostatectomy. *ACTA Urologica Italica*, p. 159-160, ISSN: 0394-2511
220. Piccinelli A, Graziotti P, Ferrazzi P, Belussi D, Hurle R, Losa A, Ranieri A, Giannone V, Lembo A (1992). Renal cells carcinoma with venous involvement: our experience in 15 cases. *ACTA Urologica Italica*, p. 89-90, ISSN: 0394-2511
221. Graziotti P, Romano C, Belussi D, Guizzetti C, Ranieri A, Tura M, Hurle R, Losa A, Monticelli L, Piccinelli A, Giardina C, Lembo A (1991). Conservative therapy of parenchymal renal carcinoma. *Archivio Italiano Di Urologia, Nefrologia, Andrologia*, vol. 63, p. 253-256, ISSN: 1120-8538
222. Francesca F, Montorsi F, Colombo R, Hurle R, Guazzoni G, Di Girolamo V, Rigatti P (1990). Antegrade ureteroscopy in the treatment of urinary stone disease. In: Free papers printed in full.
223. Grasso M, Lania C, Buonaguidi A, Hurle R, Poma R, Colombo R, Bellinzoni P, Rigatti P (1990). Evaluation of the activity of the bladder detrusor muscle and analysis of bladder function in subjects with diabetes mellitus under insulin treatment. *Minerva Urologica E Nefrologica*, vol. 42, p. 201-205, ISSN: 0393-2249
224. M Grasso, A Buonaguidi, R Mondina, C Lania, G Banfi, Hurle R, P Rigatti (1990). Sex steroid binding plasma protein as an indicator of prostatic cancer. In: Free papers printed in full.

225. F Francesca, A Bocciardi, P Consonni, Hurle R, L Nava, A Losa, P Pomba, P Rigatti (1989).
Litotriassia extracorporea con onde d'urto nel trattamento della calcolosi renale. In: Estratto da "Atti
del III Congresso Regionale A.C.O.I. - Lombardia" La Chirurgia Endocrino-Metabolica 14-15 aprile
1989 - Salice Terme.

Bibliometry

Scopus

(<https://www.scopus.com/authid/detail.uri?authorId=57192340986>) - up-date 01.11.2021:

- Overall paper 99
- Citations 1611
- Citations document 1284
- H-index 23

Google scholar

(https://scholar.google.com/citations?hl=it&user=tHt6zYAAAAJ&view_op=list_works&sortby=pubdate) -
up-date 01.11.2021:

- Overall full article + abstract 324
- Overall citations 2385
- Citations since 2016 1639
- H-index since 2016 22
- I10-index 48

Prizes and Awards

Prize

Best Poster

Awarded by

36th Annual EAU Congress, 8-12 July, Milan, Italy

For:

Survival outcomes after radical cystectomy versus conservative management for clinical T1 high grade
non-muscle invasive micropapillary bladder cancer:
a multicenter collaboration by the European Association of Urology – Young Academic Urologists

Prize

Best Poster

Awarded by

32th Annual EAU Congress, 24-28 March 2017, London, United Kingdom

For:

Active surveillance for non-muscle invasive bladder cancer (NMIBC): Result from bladder cancer Italian
active surveillance (BIAS) project (2017)

Prize

Best poster

Awarded by

XVII EAU Congress. Birmingham, 23-26 Febbraio

For:

Holmium laser enucleation of the prostate combined with mechanical morcellation: initial italian
experience in 114 patients.

**Organization or
Participation as speaker in
scientific congresses**

XXIV World Congress of the international College of Surgeons
from 03-07-1988 to 09-07-1988

Speaker at Congresso Regionale ACOI Lombardia, Report: "Complicanze nella vescica di sostituzione" from 24-05-1991 to 25-05-1991

Speaker: 1st International Symposium on Bladder Cancer. BCG Immunotherapy in Superficial Bladder Cancer: The state of the Art.

Report "Transitional cell carcinoma of the bladder T1G3: our experience with intravesical BCG" from 27-03-1992 to 27-03-1992

Speaker 65° Congresso della Società Nazionale di Urologia "1987-1991: Cistoprostatectomie 151. Sostituzione ortotopica di vescica 15. Rigore di indicazione o ossesso di prudenza?". from 31-05-1992 to 03-06-1992

Participation at the first International Symposium on Bladder Cancer from 27-03-1993 to 27-03-1993

Speaker: 42° Convegno della Società degli Urologi del Nord Italia, Report "Bacillus Calmette e Guérin nel Trattamento del tumore superficiale della vescica T1G3" from 09-09-1993 to 11-09-1993

Speaker: 3° Congresso Nazionale Società Italiana di Urologia Oncologica - SIURO, Report "La TAC nella stadiazione del tumore superficiale della vescica" from 01-12-1993 to 03-12-1993

Speaker: 4° Congresso Nazionale della Società Italiana di Urologia Oncologica – SIURO, Report "BCG nel Tumore superficiale della vescica T1G3: 4 anni di follow-up" from 09-11-1994 to 11-11-1994

Speaker: Convegno Società degli Urologi Lombardi, Report "Neoplasia vescicole T1G3: che fare?" from 17-06-1995 to 17-06-1995

Participation in courses as professor or director from 01-01-1996 to today

Speaker: AUA annual meeting, Report "Low-dose Pasteur Bacillus Calmette-Guérin regimen in stage T1 grade 3 bladder cancer therapy". from 04-05-1996 to 09-05-1996

Participation at the XIIth Annual EAU Congress from 01-09-1996 to 04-09-1996

Professor: Corso di aggiornamento Associazione Urologi Ospedalieri - AURO "Immunoterapia con BCG nel carcinoma superficiale della vescica", Report "Il BCG nel T1G3 della vescica". Milano, 13-14 dicembre 1996 - from 13-12-1996 to 14-12-1996

Speaker: 24th World Congress SIU, Report "Intravesical instillation of mitomycin C in 242 patients with superficial bladder cancer at high risk of recurrence: long term results" dal 07-09-1997 al 11-09-1997

Participation at XXIVth World Congress of the Societe Internationale d'Urologie from 07-09-1997 to 11-09-1997

Participation at XIIIth Annual EAU Congress from 21-03-1998 to 25-03-1998

Active participation: The 4th international Symposium on Predictive Oncology and Therapy from 24-10-1998 to 27-10-1998

Speaker: 4th International Symposium on Predictive Oncology and Therapy, Report "Intravesical Bacillus Calmette-Guérin in stage T1 grade 3 cancer therapy: a seven years follow-up. 4th international symposium on predictive oncology and therapy". Nice (FR), 24-27 October 1998 dal 24-10-1998 al 27-10-1998

Speaker: VI Congresso Nazionale Associazione Urologi Ospedalieri - AUrO. Report "Urological games: neoplasie vescicali superficiali". Palermo, 7-9 ottobre 1999 - from 07-10-1999 to 09-10-1999

Speaker: 5th International Symposium on Predictive Oncology and Therapy, Report "Tumor progression and survival in patients with T1G3 bladder tumor treated with low dose Pasteur bacille Calmette-Guérin". Geneva (CH), 28-31 October 1999. from 28-10-1999 to 31-10-1999

Speaker: International Symposium on Dilemmas in bladder and prostate cancer. Report "Conservative vs aggressive treatment of T1G3 Bladder tumor". Milano, novembre 1999. from 14-11-1999 to 15-11-1999

Active participation: The 5th international Symposium on Predictive Oncology and Therapy from 28-10-2000 to 31-10-2000

Speaker: 25th Congress de la Societ  Internationale d'Urologie, Report "Additional bacillus Calmette-Gu rin therapy for bladder tumor recurrence after previous successful BCG therapy". Singapore, 29 October-2 November 2000- from 29-10-2000 to 02-11-2000

Participation at 25th Congress of the Societ  Internationale d'Urologie from 29-10-2000 to 02-11-2000

Speaker: 25th Congress de la Societ  Internationale d'Urologie, Report "Standard (81mg) versus low (27mg) dose of Connaught Bacillus Calmette-Gu rin in high risk superficial bladder cancer patients: preliminary results" Singapore, 29 October-2 November 2000 - from 29-10-2000 to 02-11-2000

Speaker: 25th Congress de la Societ  Internationale d'Urologie, Report "Factors affecting recurrence and progression in superficial bladder tumor treated with bacillus Calmette-Gu rin: nine years follow-up of 193 consecutive patients". Singapore, 29 October-2 November 2000. from 29-10-2000 to 02-11-2000

Speaker: 7th congress of Mediterranean Urological Association, Video Presentation "Holmium laser enucleation of the prostate combined with mechanical morcellation". Marrakech, 3-6 September 2001 from 03-09-2001 to 06-09-2001

Participation "World Congress on Endourology and Shockwave" from 19-09-2002 to 22-09-2002

Speaker: IX Congresso nazionale Associazione Urologi Ospedalieri - AUrO, Report "Gemcitabina nella carcinoma superficiale della vescica". Torino, 20-22 ottobre 2002 - from 20-10-2002 to 22-10-2002

Participation XIVth ESPU Congress from 12-03-2003 to 15-03-2003

Participation XVIIIth Annual EAU Congress from 12-03-2003 to 15-03-2003

Professor: Corso "Adenectomia prostatica con laser ad olmio", Report "HOLEP: nostra esperienza". Bergamo, 9-13 giugno 2003 - from 09-06-2003 to 13-06-2003

Moderator of sessions and event planning from 01-01-2004 to today

Participation XIXth Annual EAU Congress from 24-03-2004 to 27-03-2004

Professor: Corso residenziale "Endourologia dell'alta via escrettrice", Report "Confezione dell'accesso per cutaneo al rene". Bergamo, 7-9 aprile 2004 - from 07-04-2004 to 09-04-2004

Professor: Corso avanzato "Adenomectomia prostatica con laser ad olmio". Report "HOLEP e morcellazione meccanica: nostra esperienza". Milano, 16 aprile 2005. from 16-04-2005 to 16-04-2005

Moderator: XII Congresso Nazionale Associazione Urologi Ospedalieri - AUrO. Moderator of "Neoplasie superficiali della vescica" session, Genova 19-22 ottobre 2005 - from 19-10-2005 to 22-10-2005

Speaker: XII congresso nazionale Associazione Urologi Ospedalieri - AUrO. Report "Novita' sul trattamento del carcinoma della vescica: ruolo della gemcitabina". Genova 19-22 ottobre 2005 - from 19-10-2005 to 22-10-2005

Speaker: XV Congresso nazionale Societ  Italiana di Urologia Oncologica - SIURO. Report "Termochemioterapia Bladder salvage". Taormina, 3-6 novembre 2005 - from 03-11-2005 to 06-11-2005

Speaker: Innovations in Urology. Report "Thermochemotherapy: current italian studies". Roma, 2 dicembre 2005 from 02-12-2005 to 02-12-2005

Participation Annual EAU Congress from 05-04-2006 to 08-04-2006

Speaker: XIII Congresso Nazionale Associazione Urologi Ospedalieri - AURO. Report "Carcinoma vescicale superficiale ad alto rischio: casi clinici". Cagliari, 4-7 ottobre 2006 - from 04-10-2006 to 07-10-2006

Professor: Corso della European School of Oncology "Il carcinoma transizionale della vescica e il carcinoma della prostata". Report "TURV e reTURV: serve altro?". Genova, 8-9 febbraio 2007 - from 08-02-2007 to 09-02-2007

Professor: Corsi teorico pratici di urologia 2007. Report "Approccio chirurgico e farmacologico al carcinoma della prostata". Roma, 12 giugno 2007 - from 12-06-2007 to 12-06-2007

Professor: Corso "Carcinoma superficiale della vescica". Report "Casi clinici". Como, 15 settembre 2007 - from 15-09-2007 to 15-09-2007

Professor: Corso "Le masse renali". Report "Agobiopsia e agoaspirato delle masse sospette". Treviglio, 13 ottobre 2007 - from 13-10-2007 to 13-10-2007

Participation at 23rd Annual EAU Congress from 26-03-2008 to 29-03-2008

Speaker: Congresso Centenario Società Italiana di Urologia – SIU. Report "Casi clinici in tumori superficiale della vescica". Roma, 22-28 settembre 2008 - from 22-09-2008 to 28-09-2008

Speaker: XV Congresso Nazionale Associazione Urologi Ospedalieri – AURO. Report "Novità: Gemcitabina e chemioipertermia". Taormina, 8-11 ottobre 2008 - from 08-10-2008 to 11-10-2008

Speaker: Convegno regionale Associazione Urologi Ospedalieri – AURO. Report "Linfoadenectomia nel tumore vescicole infiltrante". Crema, 14 novembre 2008 - from 14-11-2008 to 14-11-2008

Participaion at 24th Annual EAU Congress from 17-03-2009 to 21-03-2009

Speaker: Convegno Open Questions in Practical Urology. Report "Terapia endovesicale di seconda linea. Ruolo delle terapie device-assisted". Milano, 2-3 aprile 2009 - from 02-04-2009 to 03-04-2009

Speaker: XVI Congresso Nazionale Associazione Urologi Ospedalieri – AURO. Report "Linfoadenectomia nel tumore della vescica, infiltrante", Verona 23-26 settembre 2009 - from 23-09-2009 to 26-09-2009

Member of the Mission Briefing of the Rete Oncologica Lombarda Project "Riunione di Definizione Linee Guida - Vescica" dal 25-11-2009 al 25-11-2009

Membro della Riunione Operativa del Progetto Rete Oncologica Lombarda "Riunione di Definizione Linee Guida - Vescica" from 10-12-2009 to 10-12-2009

Speaker: UROLEAGUE. Report "Linfoadenectomia nel tumore della via escrettrice". Loano, 12-14 maggio 2010 from 12-05-2010 to 14-05-2010

Professor: Corso residenziale "Endourologia dell'alta via escrettrice". Report "Accesso percutaneo al rene". Bergamo, 10-12 giugno 2010 - from 10-06-2010 to 12-06-2010

Speaker: XVII Congresso Nazionale Associazione Urologi Ospedalieri - AURO. Report "Latest news". Roma, 22-25 settembre 2010 - from 22-09-2010 to 25-09-2010

Speaker: Convegno interregionale Società Italia di Urologia Oncologica - SIURO. Report "Endoscopia: necessaria la luce blu? HEXVIX". Peschiera del Garda, 19-20 novembre 2010 - from 19-11-2010 to 20-11-2010

Speaker: XVIII Congresso Nazionale Associazione Urologi Ospedalieri – AURO. Report "Holmium laser enucleation of the prostate (HOLEP)". Sorrento, 15-18 ottobre 2011 - from 15-10-2011 to 18-10-2011

Speaker "Wound Care and Skin Care: Temi e Approfondimenti" from 22-10-2011 to 22-10-2011

Speaker: UROLEAGUE. Report "Uro-oncologia su misura". Report: "NMIBC ad alto grado: i problemi di interpretazione anatomico-patologica alla prima tur: si può evitare la re-tur". Lido di Camaiore, 9-11 maggio 2012 - from 09-05-2012 to 11-05-2012

Speaker: UROLOMBARDIA "Il punto della situazione". Report "La terapia farmacologica dell'IPB: recenti acquisizioni riviste con il grade". Milano, 22-23 giugno 2012 - from 22-06-2012 to 23-06-2012

Professor: XIX Congresso Nazionale Associazione Urologi Ospedalieri – AURO. Course "Il laser nell'IPB". Report "Holmium laser enucleation of the prostate (holep)". Genova, 19-22 settembre 2012 - from 19-09-2012 to 22-09-2012

Professor: XIX Congresso Nazionale Associazione Urologi Ospedalieri – AURO. Head of the course "Gestione integrata del carcinoma vescicale non mio-invasivo". Genova, 19-22 Settembre 2012

Speaker: Shoot the pianist "Attualità nel trattamento dell'ipertrofia prostatica benigna". Report "Il punto sulla diagnostica dell'IPB". Como, 27 ottobre 2012 - from 27-10-2012 to 27-10-2012

Speaker: AUrO – Convegno Regionale Treviglio (BG), 15 dicembre 2012 – Ospedale di Treviglio. Modalità e indicazioni della "partial nephrectomy" open. from 15-12-2012 to 15-12-2012

Speaker: XIX Congresso Nazionale Associazione Urologi Ospedalieri – AURO Report "Collins loop en bloc resection (CLEBR) for accurate staging of primary non muscle-invasive bladder cancer: early experience". 29-31 Maggio Montecatini 2013

Speaker: XX Congresso Nazionale Associazione Urologi Ospedalieri – AURO Report "Is second - transurethral resection really needed for non-muscle invasive bladder cancer? Systematic review and metanalysis of the literature". Montecatini, 29-31 Maggio 2013

Moderator: XX Congresso Nazionale Associazione Urologi Ospedalieri – AURO. Moderator of the session "Carcinoma vescicale non mioinvasivo ad alto rischio: cosa ci dicono le linee guida in collaborazione con EAU". Montecatini Terme, 29-31 maggio 2013

Speaker: Convegno Nazionale Multidisciplinare "Il carcinoma della vescica: evidenze, dubbi, prospettive. Una revisione in tema di eziologia, diagnostica e trattamento". Report "Sorveglianza attiva nella neoplasia della vescica non muscolo infiltrante a basso rischio". Agrigento, 20-22 Giugno 2013

Course Director and Scientific Director: Convegno Regionale Associazione Urologi Ospedalieri – AURO. Sardegna, Liguria e Piemonte. "Gestione integrata del carcinoma vescicale non mio-invasivo". from 18-10-2013 to 19-10-2013

Professor: Convegno Regionale Associazione Urologi Ospedalieri – AURO. Calabria. Course "Miglioramento della gestione del NMIBC con PDD". Report "Critiche alla TURBT". Catanzaro, 16 novembre 2013

Speaker: Congresso Annuale European Association of Urology - EAU. Poster presentation "A new proposal for t1, high grade bladder cancer micro-staging definition". Madrid, 20-24 marzo 2015

Speaker: Convegno interregionale Società Italia di Urologia Oncologica - SIURO "Carcinoma della vescica: uno sguardo a 360°". Report "Trattamento bladder sparing nel tumore muscolo infiltrante della vescica". Meldola, 28 Marzo 2014

Chairman: Convegno Regionale Associazione Urologi Ospedalieri – AURO Lombardia. Rozzano, 10 maggio 2014

Moderator: Convegno Regionale Associazione Urologi Ospedalieri – AURO Lombardia. Session moderator "Sorveglianza attiva in urologia/terapie miniinvasive". Rozzano, 10 maggio 2014

Speaker: Congresso Annuale American Urological Association – AUA. Poster presentation "Collins loop En bloc resection (CLEBR) for accurate staging of primary non-muscle invasive bladder cancer: early experience". Orlando (US), 16-21 maggio 2014

Speaker: XXI Congresso Nazionale Associazione Urologi Ospedalieri – AURO. Report "Active surveillance program in recurrent non muscle invasive bladder tumor". Roma, 4-6 giugno 2014

Professor: XXI Congresso Nazionale Associazione Urologi Ospedalieri – AURO. Advanced course "Il trattamento endoscopico delle neoplasie vescicali tips and tricks". Report "Cosa sappiamo dei tumori non muscolo invasivi della vescica? Patologia e storia naturale". Roma, 4-6 giugno 2014

Moderator: XXI Congresso Nazionale Associazione Urologi Ospedalieri – AURO. Session moderator "Dai trials alla real life - chemioterapia neoadiuvante (NAC) e trattamenti bladder sparing sul carcinoma della vescica muscolo infiltrante (MIBC). In collaboration with SIURO". Roma, 4-6 giugno 2014

Speaker: Congresso Nazionale Società Italiana di Urologia – SIU. Poster presentation "Collins loop en bloc resection (CLEBR) for accurate staging of primary non-muscle invasive bladder cancer: early experience". Firenze, 27-30 settembre 2014

Speaker: Congresso Nazionale Società Italiana di Urologia – SIU. Poster presentation "Impact of a dedicated teaching program on quality outcomes of white light TURBT". Firenze, 27-30 settembre 2014

Professor: Convegno Regionale Associazione Urologi Ospedalieri – AURO. Puglia. Session Director: "Gestione integrata del carcinoma vescicale non mio-invasivo". Otranto, 3-4 ottobre 2014

Speaker: Congresso mondiale della Société Internationale de Urologie – SIU. Poster presentation "Active Surveillance Protocol NMIBC". Glasgow, 12-15 ottobre 2014

Speaker: Congresso mondiale della Société Internationale de Urologie – SIU. Poster presentation "Collins Loop En Bloc Resection (CLEBR) for Accurate Staging of Primary Non-Muscle Invasive Bladder Cancer: Early Experience". Glasgow, 12-15 ottobre 2014

Speaker: Congresso mondiale della Société Internationale de Urologie – SIU. Poster presentation "Impact of a Dedicated Teaching Program on Quality Outcomes of White Light TURBT". Glasgow, 12-15 ottobre 2014

Speaker: Congresso mondiale della Société Internationale de Urologie – SIU. Poster presentation "Is Second-Transurethral Resection Really Needed for T1 Bladder Cancer? Systematic Review, Metaanalysis of the Literature and of a Contemporary Cases Series". Glasgow, 12-15 ottobre 2014

Speaker: UROLOMBARDIA. Report "Lo stato dell'arte nella terapia dell'NMIBC". Milano, 12-13 dicembre 2014

Professor: 16th Course: Advances In Urological Oncology. Report "New Technologies in diagnosis and prognosis of non -muscle-invasive bladder cancer (NMIBC)". Erice, 14-19 aprile 2015

Speaker: Congresso Annuale American Urological Association – AUA. Poster presentation "A new proposal for t1, high grade bladder cancer micro-staging definition". New Orleans, 15-19 maggio 2015

Speaker: Congresso Annuale American Urological Association – AUA. Poster presentation "Active surveillance program in recurrent NMIBC". New Orleans, 15-19 maggio 2015

Speaker: Congresso Nazionale Società Italiana di Urologia Oncologica - SIUrO. Report: "A new proposal for t1, high grade bladder cancer micro-staging definition". Roma, 21-23 giugno 2015

Speaker: Congresso Nazionale Società Italiana di Urologia Oncologica - SIUrO. Report: "A new proposal for t1, high grade bladder cancer micro-staging definition". Roma, 21-23 giugno 2015

Professor: Congresso Nazionale Società Italiana Urologia Oncologica - SIUrO. Course: "Tumore muscolo invasivo e metastatico della vescica". Report "TURV: limite tra stadiazione e terapia". Roma, 21-23 giugno 2015

Speaker: Expert Meeting "Chasing carcinoma in situ of the bladder". Report: "The natural history of CIS: prognostic considerations". Bergamo, 25 Settembre 2015

Operator: UROLEAGUE "Re-do surgery: quando le cose non sono mai facili". Live surgery "re TUR en bloc". 27-29 settembre 2015

Speaker: Congresso Nazionale Società Italiana di Urologia - SIU. Poster presentation "Programma di sorveglianza attiva nel carcinoma vescicale non muscolo invasivo (NMIBC) recidivante". Riccione, 10-13 ottobre 2015

Professor: Società Italiana Urologia Oncologica – SIUrO. Autumn School - Core-Curriculum Uro Oncologico Certificate. Reports "Le categorie di rischio"; "Cistectomia e derivazione urinaria"; "Terapie e follow-up delle alte vie escrettrici". Torino, 12-14 novembre 2015

Speaker: Expert under Fire Società Italiana di Urologia Oncologica - SIUrO "La comunicazione medico medico". Report: "L'approccio multidisciplinare nella gestione del paziente uro-oncologico: opportunità e criticità". Bologna, 18-19 novembre 2015

Professor: Convegno Regionale Associazione Urologi Ospedalieri – AURO. Lombardia. Corso "Il trattamento endoscopico delle neoplasie vescicali tips and tricks". Report "Cosa sappiamo dei tumori non muscolo invasivi della vescica? Patologia e storia naturale". Vimercate, 21-11-2015

Speaker: UROLOMBARDIA "Strategie osservazionali (sorveglianza attiva) in urooncologia: non solo prostata". Report "SA e carcinoma della vescica". Milano, 27-28 novembre 2015

Speaker: first endourology course. Neoplasia della vescica non muscolo invasiva ad alto rischio: cosa vorremmo tutti sapere per gestire meglio i nostri pazienti, "pT1... quanti ne dobbiamo imparare a riconoscere: quale il ruolo della muscolaris mucosae?". Roma, 28-29 Gennaio 2016

Operator: Primo Corso di Endourologia "Neoplasia della Vescica non muscolo infiltrante ad alto rischio: cosa vorremmo tutti sapere per gestire meglio i nostri pazienti". Live surgery operation: "WL TURBT en bloc". Roma, 28-29 Gennaio 2016

Speaker: Congresso Annuale American Urological Association – AUA. Poster presentation "En bloc resection of bladder tumours (ERBT): multivariable analysis for prediction of recurrence at mid-term follow-up". San Diego, 6-10 maggio 2016

Moderator and Speaker: Congresso Nazionale Società Italiana di Urologia Oncologica – SIURO. Moderator structured debate: "La TUR En bloc: un update". Firenze, 9-11 giugno 2016

Speaker: Convegno Regionale Lazio Associazione Urologi Ospedalieri – AurO. Report "The best of: NMBIC – chirurgia. Fiuggi, 7-8 Ottobre 2016

Speaker: Workshop on Hexaminolevulinated for difficult cases in NMIBC, EXPERTS MEETING. Bergamo, 24 Novembre 2016

Faculty expert and speaker at congress "FOCUS ON NMIBC" from 02-12-2016 to 02-12-2016, Milan

CONSENSUS CONFERENCE TMD ANNO 2006. TEAM MULTIDISCIPLINARE URO ONCOLOGICO. UNA SFIDA COMUNE" from 13-12-2016 to 14-12-2016

Speaker at "Il Carcinoma della vescica: attualità e prospettive terapeutiche" from 02-02-2017 to 02-02-2017

Speaker and operator at II ENDOUROLOGY COURSE "Non muscle invasive bladder cancer - new horizons?" from 16-02-2017 to 17-02-2017

Participation at Investigators' Meeting for the study R39-17-01 "Phase I exploratory study of ONCOFID-P-B (PACLITAXEL - HYALURONIC ACID) administered for 12 consecutive weeks followed by maintenance therapy in BCG unresponsive/intolerant patients with Bladder Carcinoma in Situ (CIS)" 03-04-2017

Speaker "XXVII CONGRESSO NAZIONALE SIUro" from 20-04-2017 to 22-04-2017

Participant at "Cancro della vescica ad alto rischio e conservazione dell'organo" from 22-04-2017 to 22-04-2017

Training session "Phase I requirements and clinical SOPs" from 27-04-2017 to 27-04-2017

Speaker Annual Meeting AUA 2017 from 12-05-2017 to 16-05-2017

Speaker and Professor at "XXIV CONGRESSO NAZIONALE AURO.it" from 21-05-2017 to 21-05-2017

Participant at the training course "HIGH VALUE CARE AGENT" from 29-09-2017 to 29-09-2017

Faculty member at the Congress "TECHNOLOGY AND TRAINING IN ENDOUROLOGY 2017" from 08-11-2017 to 10-11-2017

Training course "Corso residenziale di Endourologia" from 15-11-2017 to 17-11-2017

Speaker at Convegno "AROUND THE BLADDER" Milan 2017 from 16-11-2017 to 17-11-2017

Speaker at EAU congress 2018 "“En bloc” thulium laser resection of NMIBC: Technique and preliminary results Copenhagen 16-20 March 2018

Coordinator of structured debate AURO national congress "Dalla chemioterapia alla immunoterapia nei tumori vescicali infiltranti" Rome 10/12 May 2018

Speaker at AUA Annual meeting 2018 18-21 May San Francisco

Speaker at EAU congress 2019 15-19 March Barcellona

Speaker at AUA Annual meeting 2019 "PD18-04 - A Phase 1 safety study of Oncofid-P-B administered for 12 consecutive weeks in BCG unresponsive/intolerant patients with bladder carcinoma in situ (CIS): Preliminary results" and "PD18-05 - XpertBladder monitor test for failure definition of patients under active surveillance for recurrent low-risk Non-Muscle Invasive Bladder Cancer (NMIBC) with negative cytology" Chicago 3-6 May

Speaker at 39th Congress of the Société Internationale d'Urologie. A Phase 1 safety study of Oncofid-P-B administered for 12 consecutive weeks in BCG unresponsive/intolerant patients with bladder carcinoma in situ (CIS): Preliminary results. Athens, 17-20 Oct 2019.

Speaker at "Congresso regionale SluRO lombardo-veneto, Dalla sorveglianza – alla terapia - al follow-up dei tumori urologici III sessione: la sorveglianza nel tumore della vescica: da NMIBC a MIBC". Strategia di sorveglianza attiva e trattamento nel NMIBC. Bergamo, 24 Jan 2020

Speaker at "ASCO Genitourinary Cancers Symposium" ONCOFID-P-B for the treatment of bcg unresponsive carcinoma in situ (cis) of bladder: preliminary results of european multicentre phase 1 study at the end of 12 consecutive weeks intensive course and during ongoing monthly maintenance phase. San Francisco, 13-15 February 2020

Speaker at "AUA 2020 Virtual Meeting" ONCOFID-P-B for the treatment of bcg unresponsive carcinoma in situ (cis) of bladder: preliminary results of european multicentre phase 1 study at the end of 12 consecutive weeks intensive course and during ongoing monthly maintenance phase. Washington, from 15-18 May 2020

Speaker at "EAU 2020 Virtual Meeting" ONCOFID-P-B for the treatment of bcg unresponsive carcinoma in situ (cis) of bladder: preliminary results of european multicentre phase 1 study at the end of 12 consecutive weeks intensive course and during ongoing monthly maintenance phase. Amsterdam, from 17-07-2020 to 26-07-2020

Faculty Expert at Educazionale SIUrO Immunoterapia in Urologia Oncologica oggi e domani (Virtual Meeting), 28 Sept 2020

Speaker at "Congresso Palinuro. Ricerca clinica e patient engagement: dalla teoria alla pratica in uro-oncologia. Trials Clinici in corso e in programmazione". Nuove opzioni terapeutiche nella lotta contro il carcinoma uroteliale: chemioterapia. Milan, 30 Nov 2020

Teacher in the following courses:

- Corso AURO education: Il Trattamento endoscopico delle neoplasie vescicali: Tips and Tricks 22/12/2020-22/06/2020 (Coordinator)
- Corso AuroEducation Webinar: Approccio diagnostico e terapeutico ai NMIBC: 8 aprile 2021

- L'importanza diagnostica e terapeutica della TURV correttamente eseguita: dalla resezione endoscopica en bloc ai Teaching Programs
- Update: Profilassi delle recidive nel carcinoma vescicale non muscolo invasivo XXVIII Congresso Nazionale 20-22 maggio (Coordinator)

Participant at "Drug development in NMIBC from scientific, regulatory, clinician e patient perspectives". A Johns Hopkins University Greenberg, Bladder Cancer Institute American Urological Association Translational Research Collaboration. March 4-6 ,2021

Speaker at Webinar: Il trattamento del tumore vescicale superficiale - La TURV En-Bloc: L'importanza dei margini laterali, 4 May 2021

Partecipant at "AUA 2021 Virtual meeting" , Las Vegas from 10-13 September 2021

Faculty expert at Live streaming Dibattito Strutturato XXXI Congresso Nazionale SIUro "Opportunità e Criticità nel trattamento delle neoplasie uroteliali avanzate" 30 Sept.2021

Teacher at Simposio Medac: Le domande più frequenti sul BCG. Available on line 30 Sept.2021

Teacher T Simposio Medac: Le domande più frequenti sulla early instillation. Available on line 30 Sept.2021

Partecipant at Survey Post Advisory Board "Hexvix e Blue Light Cystoscopy (blc)". Live Streaming 27 Oct 2021

Teacher. At Convegno Regionale Auro.IT Lombardia "Impatto della pandemia Covid-19 nella pratica Urologica ". Virtual Edition 5 Nov 2021

Teacher at Congresso Palinuro " Ricerca Clinica e patient engagement: dalla teoria alla pratica in Uro-Oncologia 2021" Tumore superficiale NMIBC, Milan 20 Nov 2021

**Management of or Attending to
Editing Boards, Editorial Series
and Encyclopedias of
recognized prestige**

Member of the North-Est Uro-Oncologic group "Il carcinoma vescicale infiltrante" from 16-12-1994 to 16-12-1994

Member of the North-Est Uro-Oncologic group "Il carcinoma del pene" from 05-05-1995 to 05-05-1995

Member of the North-Est Uro-Oncologic group "Il carcinoma metastatico del rene" from 19-01-1996 to 19-01-1996

Member of the North-Est Uro-Oncologic group "Il ruolo della chirurgia nel carcinoma renale" from 18-10-1996 to 18-10-1996

Editor of Bladder Carcinoma Guidelines. 1. Il tumore superficiale. Associazione Urologi Ospedalieri (AurO) from 01-01-2001 to 31-12-2001

Responsible Researcher, Protocollo multicentrico nazionale prospettico "Synergo: termo-chemioterapia nei tumori vescicali superficiali" from 01-01-2006 to 01-01-2011

Member of the research group "Gruppo di lavoro ROL (Rete Oncologica Lombarda)" Tumore della Vescica from 01-01-2009 to today

Member of Rete Oncologica
Lombarda Project Mission Briefing
"Riunione di Definizione Linee Guida
-Vescica" from 25-11-2009 to 25-11-
2009

Editor LUTS Guidelines correlati
all'iperplasia prostatica benigna.
Associazione Urologi Ospedalieri
(AurO) from 01-01-2011 to today

Member of ROL's group (Rete
Oncologica Lombarda) Tumore della
Vescica "Bladder Sparing" from
01-01-2014 to today

Member of SIUrO's group (Società
Italiana di Urologia Oncologica)
PRIAS ITA – Sorveglianza Attiva del
tumore della prostata PRIAS from
01-01-2014 to today

Responsabile, Protocollo
"Trattamenti chemioterapici topici
alternativi nei pazienti con tumore
della vescica di alto grado recidivi a
BCG o che rifiutano il trattamento
radicale di cistectomia" ICH-IRCCS
from 01-01-2014 to today

Responsabile, Protocollo "Bladder
cancer Italian Active Surveillance –
BIAS project" ICH-IRCCS from 01-
01-2015 to today

Co-investigator protocol SPIES
RTC - Multicentre randomized
controlled trial in which the
recurrence rate of bladder
carcinoma between SPIES assisted
and WLI assisted TURB are
compared (Principal Investigator:
Jean de la Rosette, AMC University
Hospital, Amsterdam), Clinical
Research Office of the
Endourological Society (CROES)
from 01-01-2016 to today

Reviewer Bladder Cancer
Guidelines. Associazione Italiana di
Oncologia Medica (AIOM) from 01-
01-2016 to today

Member of the Clinical Research Office of the Endourological Society (CROES) group from 01-01-2016 to today

Reviewer for the "European Urology" from 01-01-2006 to 31-01-2012

Reviewer for British Journal of Urology International from 01-01-2012 to today

Reviewer for the World Journal of Urology from 01-01-2016 to today

Member of the AIOM "Urothelial carcinoma" Guidelines Panel 2021

I authorize the processing of my personal data according to the regulations.

Yours faithfully

Dr Rofolfo Hurle
